Neoplastic Processes - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Neoplastic Processes	go back to main search page
Accession:	DOID:9008192	browse the term
Definition:	The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
Synonyms:	primary_id:	MESH:D009385

show annotations for term's descendants Sort by:
Rat (740) Mouse (746) Human (791) Chinchilla (631) Bonobo (669) Dog (724) Squirrel (641) Pig (711) Green Monkey (659) Naked Mole-rat (623) All
Genes (724)

Neoplastic Processes

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3Z1

CTD Direct Evidence: marker/mechanism

G

chromatin assembly factor 1 subunit B

protein:increased expression::

NCBI chr31:31,599,840...31,620,436
Ensembl chr31:31,600,448...31,619,784

G

ETS transcription factor ERG

CTD Direct Evidence: marker/mechanism

NCBI chr31:33,456,902...33,562,704
Ensembl chr31:33,497,209...33,515,272

G

ETS variant transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:28,665,264...28,760,919
Ensembl chr14:28,669,697...28,760,887

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 9:19,715,259...19,731,085
Ensembl chr 9:19,715,535...19,730,456

G

ETS variant transcription factor 5

CTD Direct Evidence: marker/mechanism

NCBI chr34:18,729,684...18,791,667
Ensembl chr34:18,731,943...18,789,386

G

EWS RNA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr26:22,578,782...22,608,174
Ensembl chr26:22,578,848...22,608,174

G

high density lipoprotein binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr25:51,228,194...51,296,743
Ensembl chr25:51,228,371...51,297,942

G

homeobox D9

CTD Direct Evidence: marker/mechanism

NCBI chr36:19,929,479...19,932,861

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr18:25,642,844...25,644,717
Ensembl chr18:25,642,844...25,644,717

Anaplasia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 9

CTD Direct Evidence: marker/mechanism

NCBI chr11:52,205,619...52,211,281
Ensembl chr11:52,205,668...52,211,267

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 8:36,614,045...36,656,692
Ensembl chr 8:36,614,045...36,656,692

Blast Crisis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activation induced cytidine deaminase

CTD Direct Evidence: marker/mechanism

NCBI chr27:37,064,107...37,073,791
Ensembl chr27:37,064,080...37,073,789

G

BCR activator of RhoGEF and GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr26:27,856,280...27,980,923
Ensembl chr26:27,856,082...27,978,318

G

estrogen receptor 2

NCBI chr 8:38,645,917...38,715,347
Ensembl chr 8:38,645,430...38,702,691

G

heme oxygenase 1

NCBI chr10:28,744,404...28,751,544
Ensembl chr10:28,743,795...28,751,773

G

microRNA mir-150

miRNA:decreased expression:leukocytes

NCBI chr 1:106,998,756...106,998,812
Ensembl chr 1:106,998,756...106,998,812

G

transcobalamin 2

protein:increased expression::

NCBI chr26:23,693,664...23,710,342
Ensembl chr26:23,693,773...23,709,832

Bone Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 12-lipoxygenase, 12S type

associated with Prostatic Neoplasms;

NCBI chr 5:32,026,193...32,038,698
Ensembl chr 5:31,882,501...32,038,119

G

BRCA1 interacting helicase 1

associated with Breast Neoplasms; human gene in a mouse model

NCBI chr 9:34,804,285...34,984,640
Ensembl chr 9:34,806,535...34,983,788

G

C-X-C motif chemokine receptor 4

disease_progression

associated with hepatocellular carcinoma;protein:increased expression:liver (human)

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

associated with Breast Neoplasms;mRNA:increased expression:bone element (human)

NCBI chr 1:251,985...322,081
Ensembl chr 1:252,103...322,718

G

microRNA mir-34a

susceptibility

associated with hepatocellular carcinoma;miRNA:decreased expression:serum, bone

NCBI chr 5:62,485,832...62,485,897
Ensembl chr 5:62,485,832...62,485,897

G

matrix metallopeptidase 13

associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human)

NCBI chr 5:28,793,568...28,864,832
Ensembl chr 5:28,850,522...28,864,121

G

platelet derived growth factor D

associated with prostate carcinoma

NCBI chr 5:27,863,739...28,092,376
Ensembl chr 5:27,863,591...28,089,936

Carcinogenesis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 9:53,118,462...53,262,092
Ensembl chr 9:53,119,641...53,261,307

G

ADP-ribosylarginine hydrolase

NCBI chr33:23,218,633...23,226,844
Ensembl chr33:23,218,101...23,224,667

G

aldo-keto reductase family 1 member A1

CTD Direct Evidence: marker/mechanism

NCBI chr15:14,792,398...14,808,805
Ensembl chr15:14,742,012...14,808,592

G

AKT serine/threonine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:72,317,399...72,335,686
Ensembl chr 8:72,317,869...72,335,193

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr16:8,222,909...8,318,179
Ensembl chr16:8,222,907...8,317,906

G

caveolin 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:55,458,934...55,494,563
Ensembl chr14:55,461,048...55,492,935

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr11:41,223,316...41,226,056
Ensembl chr11:41,223,315...41,264,379

G

cut like homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:7,820,154...8,108,236
Ensembl chr 6:7,820,764...8,195,631

G

DNA methyltransferase 1

disease_progression

NCBI chr20:50,872,213...50,928,352
Ensembl chr20:50,879,527...50,928,029

G

DNA methyltransferase 3 alpha

disease_progression

NCBI chr17:19,489,524...19,563,074
Ensembl chr17:19,492,193...19,563,902

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:48,550,836...48,636,776
Ensembl chr10:48,551,410...48,634,844

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:22,760,373...22,785,367
Ensembl chr 9:22,759,256...22,785,294

G

GATA binding protein 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:28,068,143...28,098,445
Ensembl chr 2:28,069,051...28,087,760

G

ISG15 ubiquitin like modifier

CTD Direct Evidence: marker/mechanism

NCBI chr 5:56,230,879...56,237,354
Ensembl chr 5:56,236,318...56,404,695

G

KRAS proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

PMID:26595770 PMID:29247004

NCBI chr27:22,261,753...22,296,704
Ensembl chr27:22,257,941...22,293,369

G

small nucleolar RNA SNORD50

CTD Direct Evidence: marker/mechanism

G

mitogen-activated protein kinase kinase kinase 8

PMID:15287022 PMID:23533274

RGD:151356924 RGD:151356978

NCBI chr 2:16,717,845...16,740,816
Ensembl chr 2:16,720,596...16,740,515

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr14:55,599,047...55,711,626
Ensembl chr14:55,598,337...55,724,027

G

microRNA mir-143

CTD Direct Evidence: therapeutic

NCBI chr 4:59,534,535...59,534,589
Ensembl chr 4:59,534,535...59,534,594

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr36:20,989,205...21,087,044
Ensembl chr36:20,989,360...21,012,524

G

platelet activating factor acetylhydrolase 1b regulatory subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:46,648,057...46,731,259
Ensembl chr 9:46,648,052...46,771,400

G

POU class 5 homeobox 1

CTD Direct Evidence: marker/mechanism

G

secreted protein acidic and cysteine rich

CTD Direct Evidence: marker/mechanism

NCBI chr 4:57,659,541...57,682,147
Ensembl chr 4:57,659,650...57,681,711

G

TNF superfamily member 8

CTD Direct Evidence: marker/mechanism

NCBI chr11:68,979,498...69,006,898
Ensembl chr11:68,982,360...69,007,355

Circulating Neoplastic Cells

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:22,760,373...22,785,367
Ensembl chr 9:22,759,256...22,785,294

Liver Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

associated with colorectal cancer;mRNA:increased expression:liver (mouse)

NCBI chr 9:11,497,182...11,516,362
Ensembl chr 9:11,497,182...11,516,358

G

B-Raf proto-oncogene, serine/threonine kinase

severity

associated with skin melanoma;DNA:missense mutations:cds:
associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human)
associated with colorectal cancer;DNA:mutations:multiple
associated with colorectal cancer;DNA:mutation:cds:
associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human)

PMID:22331825 PMID:23010994 PMID:26775732 PMID:27737491 PMID:28787433

RGD:11554843 RGD:14696791 RGD:15039394 RGD:18337264 RGD:18337265

NCBI chr16:8,222,909...8,318,179
Ensembl chr16:8,222,907...8,317,906

G

C-C motif chemokine ligand 2

disease_progression

associated with colorectal cancer

NCBI chr 9:39,008,187...39,009,932

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

NCBI chr 9:37,817,409...37,823,852
Ensembl chr 9:37,817,305...37,823,852

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

NCBI chr27:40,563,306...40,593,362
Ensembl chr27:40,564,921...40,594,255

G

cyclin G1

treatment

human cells in mouse model

NCBI chr 4:47,800,697...47,808,259
Ensembl chr 4:47,801,575...47,808,211

G

CD44 molecule

associated with Breast Neoplasm;protein:increased expression:liver

NCBI chr18:32,735,493...32,826,483
Ensembl chr18:32,737,907...32,827,107

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

NCBI chr27:38,411,009...38,440,367
Ensembl chr27:38,411,075...38,439,958

G

C-X-C motif chemokine ligand 10

treatment

associated with colon carcinoma;

NCBI chr32:598,406...599,925
Ensembl chr32:597,987...599,979

G

C-X-C motif chemokine ligand 12

ameliorates

associated with colorectal cancer; human cells in mouse model

NCBI chr28:2,895,916...2,903,543

G

C-X-C motif chemokine ligand 8

associated with colorectal cancer; human colon adenocarcinoma cells in a mouse model

NCBI chr13:62,435,035...62,438,354
Ensembl chr13:62,434,422...62,438,354

G

C-X-C motif chemokine receptor 4

ameliorates

associated with colorectal cancer; human cells in mouse model
human cells in mouse model; associated with colorectal cancer

PMID:29436696 PMID:30789971

RGD:151893289 RGD:152023643

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

death domain associated protein

exacerbates

associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human)
associated with colon cancer; mRNA:decreased expression:liver (human)
associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human)

PMID:30339629 PMID:30342802 PMID:31942198

RGD:152025194 RGD:152025199 RGD:152025203

NCBI chr12:2,755,960...2,760,687
Ensembl chr12:2,755,960...2,761,340

G

discoidin domain receptor tyrosine kinase 1

treatment

human cells in mouse model; nilotinib
mRNA:increased expression:liver (mouse)

PMID:29438985 PMID:30666650 PMID:33110221

RGD:151347537 RGD:151347685 RGD:151347840

NCBI chr12:653,800...671,190
Ensembl chr12:653,807...670,543

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with colon carcinoma
associated with melanoma;

PMID:21701781 PMID:22071959

RGD:150429701 RGD:150429713

NCBI chr38:20,002,984...20,152,930
Ensembl chr38:20,008,057...20,152,275

G

dedicator of cytokinesis 6

ameliorates

associated with stomach cancer;

NCBI chr20:50,029,354...50,066,829
Ensembl chr20:50,029,369...50,066,829

G

F-box and WD repeat domain containing 7

disease_progression

associated with colorectal cancer;

NCBI chr15:50,187,579...50,417,188
Ensembl chr15:50,189,240...50,417,195

G

fibroblast growth factor receptor 1

associated with colorectal cancer;mRNA:increased expression:colorectal mucosa:

NCBI chr16:27,029,902...27,080,514
Ensembl chr16:27,031,588...27,078,261

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

NCBI chr17:22,340,469...22,364,994
Ensembl chr17:22,341,322...22,361,772

G

glypican 3

protein:increased expression:blood serum (human)

NCBI chr X:104,313,426...104,751,215
Ensembl chr X:104,313,591...104,751,756

G

hydroxymethylbilane synthase

associated with colon adenocarcinoma;protein:decreased activity:liver(rat)

NCBI chr 5:14,767,306...14,775,205
Ensembl chr 5:14,767,666...14,775,082

G

interleukin 2

treatment

associated with colon carcinoma
associated with Colorectal Neoplasms, Carcinoma, Hepatocellular;

PMID:9354462 PMID:11591892

RGD:14928215 RGD:8663446

NCBI chr19:17,750,780...17,756,394
Ensembl chr19:17,750,780...17,756,394

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

NCBI chr20:3,241,058...3,403,394
Ensembl chr20:3,241,052...3,522,859

G

mitogen-activated protein kinase kinase 7

associated with colon cancer;protein:increased expression:colon (human)

NCBI chr20:52,594,450...52,604,236
Ensembl chr20:52,594,536...52,602,150

G

microRNA mir-148b

exacerbates

associated with stomach cancer;

NCBI chr27:975,146...975,206
Ensembl chr27:975,131...975,220

G

microRNA mir-155

NCBI chr31:21,078,768...21,078,828
Ensembl chr31:21,078,758...21,078,833

G

microRNA mir-200b

associated with colorectal cancer;RNA:increased expression:liver:

NCBI chr 5:56,368,400...56,368,479
Ensembl chr 5:56,368,400...56,368,479

G

microRNA mir-200c

associated with colorectal cancer;RNA:increased expression:liver:

NCBI chr27:38,082,097...38,082,159
Ensembl chr27:38,082,091...38,082,169

G

microRNA mir-223

disease_progression

associated with colorectal cancer;

NCBI chr X:50,838,131...50,838,233
Ensembl chr X:50,838,131...50,838,233

G

microRNA mir-494

exacerbates

associated with pancreatic ductal adenocarcinoma;

NCBI chr 8:69,261,385...69,261,465
Ensembl chr 8:69,261,385...69,261,465

G

MPL proto-oncogene, thrombopoietin receptor

exacerbates
severity

associated with pancreatic cancer; protein:increased expression:liver, pancreas (human)
associated with colorectal carcinoma;protein:increased expression:colorectum (human)
associated with pancreatic ductal adenocarcinoma; human cells in mouse model

PMID:23747337 PMID:30770989

RGD:126925751 RGD:126925752

NCBI chr15:16,815,102...16,825,321
Ensembl chr15:16,815,294...16,825,350

G

NRAS proto-oncogene, GTPase

susceptibility

associated with colorectal cancer;DNA:mutations:exons (human)
associated with melanoma;DNA:mutations: exons (human)
human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human)

PMID:26799184 PMID:28011498 PMID:28787433

RGD:14696774 RGD:14696791 RGD:14696792

NCBI chr17:52,411,733...52,418,788
Ensembl chr17:52,411,733...52,418,788

G

protein tyrosine phosphatase receptor type B

treatment

mouse tumor cells in mouse recipient

NCBI chr10:12,267,891...12,384,522
Ensembl chr10:12,241,716...12,384,435

G

RPTOR independent companion of MTOR complex 2

disease_progression

mRNA:increased expression:liver (human)

NCBI chr 4:69,903,393...70,013,168
Ensembl chr 4:69,936,379...70,010,566

G

ring finger protein 43

associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human)

NCBI chr 9:32,996,668...33,061,781
Ensembl chr 9:32,997,937...33,060,313

G

solute carrier family 3 member 2

severity

associated with colon adenocarcinoma

NCBI chr18:53,810,468...53,819,021
Ensembl chr18:53,810,398...53,819,021

G

solute carrier family 7 member 5

severity

associated with colon adenocarcinoma
associated with colon cancer

PMID:11718450 PMID:11745822

RGD:151361129 RGD:151361130

NCBI chr 5:65,313,105...65,343,858
Ensembl chr 5:65,313,105...65,343,858

G

SMAD family member 4

treatment

associated with colorectal carcinoma;protein:decreased expression:colorectum:
associated with colorectal carcinoma; DNA:mutations: :

PMID:17390050 PMID:29551247

RGD:18937000 RGD:21066338

NCBI chr 1:23,875,989...23,930,027
Ensembl chr 1:23,882,139...23,969,405

G

SRY-box transcription factor 30

ameliorates

NCBI chr 4:52,587,163...52,615,945
Ensembl chr 4:52,587,355...52,615,945

G

SRC proto-oncogene, non-receptor tyrosine kinase

disease_progression

associated with colon cancer;protein:increased activity:colon

NCBI chr24:25,982,499...26,019,748
Ensembl chr24:25,999,048...26,018,077

G

vascular endothelial growth factor A

associated with colorectal carcinoma;mRNA,protein:increased expression:liver:

NCBI chr12:12,209,032...12,224,978
Ensembl chr12:12,208,231...12,224,965

lung metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 28

ameliorates

associated with lung adenocarcinoma;
associated with lung carcinoma, breast carcinoma

PMID:22636800 PMID:26800504

RGD:11531771 RGD:153297785

NCBI chr25:33,092,645...33,147,791
Ensembl chr25:33,092,628...33,264,710

G

Rho GTPase activating protein 5

associated with Mammary Neoplasms, Experimental

NCBI chr 8:11,190,663...11,269,353
Ensembl chr 8:11,204,696...11,267,086

G

AT-rich interaction domain 2

exacerbates

associated with hepatocellular carcinoma,

NCBI chr27:8,411,092...8,579,735
Ensembl chr27:8,412,377...8,579,882

G

alpha-2-glycoprotein 1, zinc-binding

ameliorates

associated with hepatocellular carcinoma;

PMID:26902423 PMID:27993894

RGD:153350132 RGD:153350133

NCBI chr 6:9,622,991...9,629,154
Ensembl chr 6:9,622,992...9,629,154

G

carbonic anhydrase 12

ameliorates

associated with breast cancer;

NCBI chr30:27,903,460...27,957,162
Ensembl chr30:27,905,837...27,957,742

G

Cbl proto-oncogene B

severity

associated with stomach carcinoma;

NCBI chr33:11,255,453...11,665,755
Ensembl chr33:11,199,863...11,530,810

G

cyclin G1

NCBI chr 4:47,800,697...47,808,259
Ensembl chr 4:47,801,575...47,808,211

G

chromodomain helicase DNA binding protein 4

ameliorates

associated with human colon adenocarcinoma cells in a mouse model

NCBI chr27:38,411,009...38,440,367
Ensembl chr27:38,411,075...38,439,958

G

collagen type X alpha 1 chain

ameliorates

associated with H1299 cell

NCBI chr12:71,803,372...71,810,049
Ensembl chr12:71,798,692...71,809,399

G

C-X-C motif chemokine receptor 4

ameliorates

associated with nasopharynx carcinoma; human cells in mouse model
associated with colorectal cancer; human cells in mouse model
associated with osteosarcoma and melanoma

PMID:16000558 PMID:18071913 PMID:26498029 PMID:31938138

RGD:151665329 RGD:151893515 RGD:152023752 RGD:152177473

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

discoidin domain receptor tyrosine kinase 1

NCBI chr12:653,800...671,190
Ensembl chr12:653,807...670,543

G

discoidin domain receptor tyrosine kinase 2

exacerbates

associated with tongue squamous cell carcinoma;

NCBI chr38:20,002,984...20,152,930
Ensembl chr38:20,008,057...20,152,275

G

fatty acid synthase

associated with head and neck squamous cell carcinoma

NCBI chr 9:233,105...249,573
Ensembl chr 9:232,963...249,092

G

FOS like 2, AP-1 transcription factor subunit

human cells in mouse model

NCBI chr17:22,340,469...22,364,994
Ensembl chr17:22,341,322...22,361,772

G

hypoxia inducible lipid droplet associated

human cells in mouse model

NCBI chr14:7,957,811...7,959,878

G

IQ motif and Sec7 domain ArfGEF 1

human cells in mouse model

NCBI chr20:3,241,058...3,403,394
Ensembl chr20:3,241,052...3,522,859

G

integrin subunit alpha V

treatment

human cells in rat model

NCBI chr36:28,815,215...28,890,569
Ensembl chr36:28,804,013...28,887,430

G

mitogen-activated protein kinase kinase kinase 1

ameliorates

associated with breast carcinoma

NCBI chr 2:43,918,210...43,996,817
Ensembl chr 2:43,917,604...43,995,209

G

mitogen-activated protein kinase kinase kinase 8

ameliorates

associated with clear cell renal cell carcinoma

NCBI chr 2:16,717,845...16,740,816
Ensembl chr 2:16,720,596...16,740,515

G

microRNA mir-423a

human cells in mouse model

NCBI chr 9:44,155,913...44,155,971

G

microRNA mir-494

ameliorates

associated with hepatocellular carcinoma

PMID:25820676 PMID:28055013

RGD:155900754 RGD:156430322

NCBI chr 8:69,261,385...69,261,465
Ensembl chr 8:69,261,385...69,261,465

G

NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor

associated with hepatocellular carcinoma

NCBI chr26:22,816,869...22,896,103
Ensembl chr26:22,816,551...22,894,196

G

neurotrophic receptor tyrosine kinase 3

ameliorates

associated with mammary carcinoma

NCBI chr 3:51,131,470...51,491,112
Ensembl chr 3:51,138,751...51,513,024

G

PAXIP1 associated glutamate rich protein 1

human cells in mouse model

NCBI chr 6:17,876,740...17,879,546

G

protein tyrosine phosphatase receptor type B

treatment

NCBI chr10:12,267,891...12,384,522
Ensembl chr10:12,241,716...12,384,435

G

RPTOR independent companion of MTOR complex 2

human cells in mouse model

PMID:20978191 PMID:29809146

RGD:152995469 RGD:152995516

NCBI chr 4:69,903,393...70,013,168
Ensembl chr 4:69,936,379...70,010,566

G

regulatory associated protein of MTOR complex 1

NCBI chr 9:1,012,512...1,345,872
Ensembl chr 9:1,013,603...1,344,148

G

splicing factor 3b subunit 4

human cells in mouse model

NCBI chr17:59,208,989...59,214,643
Ensembl chr17:59,208,990...59,213,991

G

SRY-box transcription factor 30

ameliorates

NCBI chr 4:52,587,163...52,615,945
Ensembl chr 4:52,587,355...52,615,945

G

SRC proto-oncogene, non-receptor tyrosine kinase

treatment
ameliorates

associated with breast cancer;
associated with nasopharynx carcinoma;

PMID:15753384 PMID:27078847

RGD:150521726 RGD:1581400

NCBI chr24:25,982,499...26,019,748
Ensembl chr24:25,999,048...26,018,077

Lymphatic Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 13

susceptibility

DNA:amplification:cds: (human, male)

NCBI chr18:136,338...353,974
Ensembl chr18:135,690...352,871

G

ADAM metallopeptidase domain 28

associated with breast cancer;DNA:hypermethylation:

NCBI chr25:33,092,645...33,147,791
Ensembl chr25:33,092,628...33,264,710

G

adhesion G protein-coupled receptor B1

disease_progression

associated with stomach cancer;

NCBI chr13:36,627,791...36,649,013
Ensembl chr13:36,614,498...36,690,936

G

activation induced cytidine deaminase

associated with stomach cancer;protein:increased expression:stomach (human)

NCBI chr27:37,064,107...37,073,791
Ensembl chr27:37,064,080...37,073,789

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr20:52,942,090...52,948,126
Ensembl chr20:52,942,259...52,947,475

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011

G

aquaporin 3

CTD Direct Evidence: marker/mechanism

NCBI chr11:50,517,509...50,524,565

G

Rho GTPase activating protein 5

associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx

NCBI chr 8:11,190,663...11,269,353
Ensembl chr 8:11,204,696...11,267,086

G

ASXL transcriptional regulator 1

associated with colorectal cancer

NCBI chr24:21,725,126...21,804,745
Ensembl chr24:21,661,059...21,802,815

G

AXL receptor tyrosine kinase

associated Pancreatic Neoplasms

NCBI chr 1:112,699,679...112,727,434
Ensembl chr 1:112,700,365...112,726,960

G

BAG cochaperone 1

disease_progression

associated with Breast Neoplasms:protein:increased expression:breast

NCBI chr11:50,348,833...50,363,532
Ensembl chr11:50,350,999...50,363,581

G

BMP and activin membrane bound inhibitor

associated with stomach cancer; protein:increased expression: :

NCBI chr 2:17,453,628...17,459,812
Ensembl chr 2:17,455,243...17,462,346

G

BarH like homeobox 2

associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucosa

NCBI chr 6:57,971,077...57,977,197
Ensembl chr 6:57,971,018...57,977,211

G

BCL2 apoptosis regulator

associated with Breast Neoplasms;protein:increased expression:lymph node

NCBI chr 1:13,733,849...13,900,653
Ensembl chr 1:13,731,406...13,900,658

G

BCL2 interacting killer

associated with cholangiocarcinoma;DNA:CNV::

NCBI chr10:22,417,374...22,433,055

G

baculoviral IAP repeat containing 5

disease_progression

associated with Breast Neoplasms
associated with Cervix Neoplasms;mRNA:splice variant

PMID:17285241 PMID:17877643

RGD:2293098 RGD:2293103

NCBI chr 9:2,930,308...2,959,307

G

B-Raf proto-oncogene, serine/threonine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr16:8,222,909...8,318,179
Ensembl chr16:8,222,907...8,317,906

G

bromodomain containing 7

severity

protein:increased expression:lung:

NCBI chr 2:64,966,636...65,002,800
Ensembl chr 2:64,966,392...65,002,799

G

basigin

disease_progression

associated with Breast Neoplasms

NCBI chr20:57,942,703...57,951,089
Ensembl chr20:57,943,276...57,951,061

G

Bruton tyrosine kinase

disease_progression

associated with lung adenocarcinoma;protein:increased expression:lung (human)

NCBI chr X:75,270,952...75,302,663
Ensembl chr X:75,270,979...75,302,562

G

carbonic anhydrase 9

associated with Cervix Neoplasms

NCBI chr11:52,205,619...52,211,281
Ensembl chr11:52,205,668...52,211,267

G

calcium binding protein 39

associated with pancreatic cancer;RNA:increased expression:pancreas

NCBI chr25:42,752,798...42,801,257
Ensembl chr25:42,703,332...42,799,279

G

caspase 9

associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human)

NCBI chr 2:82,033,759...82,076,710
Ensembl chr 2:82,031,563...82,090,484

G

caveolin 1

disease_progression

associated with Melanoma

NCBI chr14:55,458,934...55,494,563
Ensembl chr14:55,461,048...55,492,935

G

Cbl proto-oncogene

associated with stomach carcinoma;protein:increased expression:stomach

NCBI chr 5:14,600,409...14,676,974
Ensembl chr 5:14,607,013...14,676,956

G

Cbl proto-oncogene B

associated with stomach carcinoma;

NCBI chr33:11,255,453...11,665,755
Ensembl chr33:11,199,863...11,530,810

G

cyclin D2

associated with colorectal cancer;protein:increased expression:colorectum

NCBI chr27:40,563,306...40,593,362
Ensembl chr27:40,564,921...40,594,255

G

cyclin E1

associated with Carcinoma, Transitional Cell;protein:decreased expression

NCBI chr 1:121,688,622...121,697,533
Ensembl chr 1:121,688,796...121,697,649

G

cyclin H

CTD Direct Evidence: marker/mechanism

NCBI chr 3:21,046,477...21,067,305
Ensembl chr 3:21,046,472...21,178,315

G

C-C motif chemokine receptor 5

associated with Breast Neoplasms;mRNA:increased expression:lymph node

NCBI chr20:42,293,288...42,297,952
Ensembl chr20:42,294,996...42,297,952

G

CD274 molecule

CTD Direct Evidence: marker/mechanism

NCBI chr 1:93,461,735...93,605,772
Ensembl chr 1:93,585,518...93,603,522

G

CD40 molecule

associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human)

NCBI chr24:33,352,992...33,383,488
Ensembl chr24:33,372,930...33,383,301

G

CD44 molecule

associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach

NCBI chr18:32,735,493...32,826,483
Ensembl chr18:32,737,907...32,827,107

G

cadherin 1

associated with Breast Neoplasms
associated with Cervix Neoplasms

PMID:17649807 PMID:18097581

RGD:2289498 RGD:2296046

NCBI chr 5:80,757,508...80,834,878
Ensembl chr 5:80,757,508...80,834,878

G

cyclin dependent kinase inhibitor 1A

associated with Eyelid Neoplasms;
associated with Oral Squamous Cell Carcinoma;

PMID:15817070 PMID:19628749

RGD:8661799 RGD:8662374

NCBI chr12:5,746,898...5,755,103
Ensembl chr12:5,745,852...5,892,281

G

cyclin dependent kinase inhibitor 1B

associated with Breast Neoplasms
associated with non-small cell lung carcinoma

PMID:12015771 PMID:28601655

RGD:13673921 RGD:2293607

NCBI chr27:33,609,154...33,613,558
Ensembl chr27:33,611,760...33,612,906

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr11:41,223,316...41,226,056
Ensembl chr11:41,223,315...41,264,379

G

claudin 1

CTD Direct Evidence: marker/mechanism

NCBI chr34:22,303,058...22,319,101
Ensembl chr34:22,303,850...22,319,033

G

CLPTM1 like

associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus

NCBI chr34:11,263,274...11,277,666
Ensembl chr34:11,263,162...11,277,436

G

clusterin

associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human)

NCBI chr25:29,982,811...29,999,565
Ensembl chr25:29,982,811...29,999,563

G

catechol-O-methyltransferase

associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human)

NCBI chr26:29,359,930...29,381,854
Ensembl chr26:29,360,356...29,366,008

G

C-reactive protein

susceptibility

associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human)

NCBI chr38:22,396,787...22,398,180
Ensembl chr38:22,396,263...22,399,166

G

colony stimulating factor 1 receptor

associated with Breast Neoplasms

NCBI chr 4:58,980,699...59,010,683
Ensembl chr 4:58,980,788...59,010,510

G

cytotoxic T-lymphocyte associated protein 4

associated with Prostatic Neoplasms

NCBI chr37:12,647,712...12,653,874
Ensembl chr37:12,634,563...12,653,874

G

catenin alpha 1

associated with Breast Neoplasms

NCBI chr11:26,273,322...26,459,497
Ensembl chr11:26,143,013...26,459,091

G

catenin beta 1

associated with Breast Neoplasms;protein:decreased expression

NCBI chr23:10,559,722...10,572,933
Ensembl chr23:10,559,718...10,572,927

G

C-X-C motif chemokine ligand 12

disease_progression

associated with stomach cancer;mRNA:increased expression:stomach (human)

NCBI chr28:2,895,916...2,903,543

G

C-X-C motif chemokine receptor 4

associated with nasopharynx carcinoma; protein:increased expression:lymph node (human)

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

cytochrome c, somatic

associated with non-small cell lung carcinoma; protein:decreased expression:serum

NCBI chr14:38,579,446...38,581,983
Ensembl chr14:38,579,446...38,581,983

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA, protein:increased expression:mouth (human)
mRNA:increased expression:kidney, lymph nodes (human)

PMID:27020590 PMID:31253192

RGD:151347620 RGD:151347863

NCBI chr12:653,800...671,190
Ensembl chr12:653,807...670,543

G

discoidin domain receptor tyrosine kinase 2

disease_progression

associated with oral squamous cell carcinoma

NCBI chr38:20,002,984...20,152,930
Ensembl chr38:20,008,057...20,152,275

G

DNA methyltransferase 3 beta

associated with Carcinoma, Pancreatic Ductal;

NCBI chr24:22,096,386...22,123,378
Ensembl chr24:22,096,349...22,122,900

G

estrogen receptor binding site associated antigen 9

associated with Breast Neoplasms;protein:increased expression:breast
associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node

PMID:12054692 PMID:12845666 PMID:17187007

RGD:2289847 RGD:2289856 RGD:2298489

NCBI chr13:10,081,700...10,099,737
Ensembl chr13:10,081,695...10,099,501

G

epidermal growth factor receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

NCBI chr18:5,983,669...6,044,092
Ensembl chr18:5,982,770...6,042,631

G

euchromatic histone lysine methyltransferase 2

associated with Esophageal Squamous Cell Carcinoma;
associated with Melanoma;

PMID:24658378 PMID:24805087

RGD:9590069 RGD:9590071

NCBI chr12:1,341,202...1,354,602
Ensembl chr12:1,341,191...1,354,584

G

EPH receptor A2

protein:increased expression:esophagus (human)

NCBI chr 2:81,534,130...81,561,722
Ensembl chr 2:81,534,125...81,561,725

G

erb-b2 receptor tyrosine kinase 2

disease_progression

associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V
associated with lung adenocarcinoma; protein:increased expression:lung (human)
CTD Direct Evidence: marker/mechanism
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder

PMID:18097576 PMID:18237248 PMID:21532492 PMID:21966491

RGD:153344600 RGD:2289925 RGD:2289926

NCBI chr 9:22,760,373...22,785,367
Ensembl chr 9:22,759,256...22,785,294

G

erb-b2 receptor tyrosine kinase 3

associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus
associated with head and neck squamous cell carcinoma

PMID:17634423 PMID:20604875

RGD:126790467 RGD:2289944

NCBI chr10:406,856...424,746
Ensembl chr10:406,633...424,264

G

erb-b2 receptor tyrosine kinase 4

disease_progression
severity

associated with oral squamous cell carcinoma
associated with lung non-small cell carcinoma
associated with colorectal adenocarcinoma

PMID:16507107 PMID:21324275 PMID:27444519

RGD:126781762 RGD:126781766 RGD:126790471

NCBI chr37:19,029,647...20,134,576
Ensembl chr37:19,037,217...20,134,426

G

Fas cell surface death receptor

susceptibility

associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A

NCBI chr26:38,738,811...38,763,298
Ensembl chr26:38,737,611...38,763,321

G

fibroblast growth factor 1

associated with Cervix Neoplasms;mRNA:increased expression:lymph node

NCBI chr 2:37,467,431...37,554,770
Ensembl chr 2:37,470,985...37,554,619

G

fibroblast growth factor receptor 2

associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human)

NCBI chr28:31,303,882...31,411,015
Ensembl chr28:31,303,894...31,411,621

G

fms related receptor tyrosine kinase 3

disease_progression

associated with Prostatic Neoplasms

NCBI chr25:11,551,372...11,670,891
Ensembl chr25:11,581,206...11,692,284

G

forkhead box A1

associated with lung non-small cell carcinoma; mRNA:increased expression: :

NCBI chr 8:16,072,629...16,083,105
Ensembl chr 8:16,079,140...16,083,807

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr20:20,438,631...21,020,516
Ensembl chr20:20,788,433...21,016,397

G

glutathione peroxidase 3

associated with stomach carcinoma; DNA:hypermethylation:promoter

NCBI chr 4:58,200,671...58,209,010
Ensembl chr 4:58,200,672...58,209,010

G

glutamate ionotropic receptor kainate type subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr12:58,932,754...59,991,305
Ensembl chr12:59,355,017...59,990,408

G

high mobility group box 1

associated with Adenocarcinoma, Colon

NCBI chr25:9,431,223...9,558,167
Ensembl chr25:9,431,218...9,558,165

G

intercellular adhesion molecule 1

associated with Breast Neoplasms

NCBI chr20:50,818,715...50,827,914
Ensembl chr20:50,818,715...50,827,914

G

immediate early response 2

NCBI chr20:49,071,243...49,074,184
Ensembl chr20:49,072,234...49,072,902

G

interleukin 13

associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node

NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388

G

interleukin 18

associated with Breast Neoplasms;protein:increased expression:serum

NCBI chr 5:20,972,742...20,995,327
Ensembl chr 5:20,972,871...20,995,348

G

inhibitor of growth family member 4

CTD Direct Evidence: therapeutic

NCBI chr27:38,371,656...38,379,251
Ensembl chr27:38,371,766...38,379,029

G

IQ motif and Sec7 domain ArfGEF 1

disease_progression

associated with lung adenocarcinoma; protein:increased expression:lung (human)

NCBI chr20:3,241,058...3,403,394
Ensembl chr20:3,241,052...3,522,859

G

integrin subunit beta 1

associated with non-small cell lung carcinoma,

NCBI chr 2:3,728,472...3,757,696
Ensembl chr 2:3,670,596...3,756,961

G

potassium inwardly rectifying channel subfamily J member 12

CTD Direct Evidence: marker/mechanism

NCBI chr 5:42,819,412...42,860,916
Ensembl chr 5:42,850,372...42,860,899

G

kinase insert domain receptor

treatment

associated with Squamous Cell Carcinoma of the Tongue

NCBI chr13:47,442,861...47,484,574
Ensembl chr13:47,442,764...47,485,042

G

KiSS-1 metastasis suppressor

CTD Direct Evidence: therapeutic

NCBI chr38:768,333...774,328
Ensembl chr38:768,585...773,382

G

KLF transcription factor 7

CTD Direct Evidence: therapeutic

NCBI chr37:15,515,563...15,607,345
Ensembl chr37:15,521,622...15,605,824

G

lysine methyltransferase 2D

associated with stomach cancer

NCBI chr27:5,516,866...5,556,303
Ensembl chr27:5,521,804...5,553,490

G

laminin subunit gamma 2

associated with lung squamous cell carcinoma;

NCBI chr 7:16,543,541...16,625,304
Ensembl chr 7:16,569,086...16,624,085

G

mesothelin

CTD Direct Evidence: marker/mechanism

NCBI chr 6:39,827,985...39,834,945

G

leucine rich repeat containing 59

CTD Direct Evidence: marker/mechanism

NCBI chr 9:26,350,300...26,364,021
Ensembl chr 9:26,351,734...26,364,082

G

macrophage immunometabolism regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 3:7,956,865...7,968,964

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr14:55,599,047...55,711,626
Ensembl chr14:55,598,337...55,724,027

G

microRNA mir-125a

associated with stomach cancer;

NCBI chr 1:105,400,273...105,400,332
Ensembl chr 1:105,400,270...105,400,337

G

microRNA mir-152

associated with breast cancer

NCBI chr 9:24,335,161...24,335,219
Ensembl chr 9:24,335,146...24,335,225

G

microRNA mir-155

disease_progression

associated with colon cancer

PMID:26885061 PMID:27856635 PMID:29893326

RGD:21079444 RGD:21079446 RGD:21409756

NCBI chr31:21,078,768...21,078,828
Ensembl chr31:21,078,758...21,078,833

G

microRNA mir-187

associated with oral squamous cell carcinoma; RNA:increased expression:plasma

NCBI chr 7:54,261,943...54,262,010
Ensembl chr 7:54,261,943...54,262,010

G

microRNA mir-224

associated with colorectal cancer; mRNA:decreased expression:colorectal mucosa:

NCBI chr X:119,925,345...119,925,413
Ensembl chr X:119,925,345...119,925,413

G

microRNA mir-30a

associated with Colorectal Neoplasms

NCBI chr12:33,783,894...33,783,956
Ensembl chr12:33,783,891...33,783,961

G

microRNA mir-335

associated with stomach cancer; RNA:decreased expression:stomach

NCBI chr14:6,444,861...6,444,918
Ensembl chr14:6,444,847...6,444,932

G

microRNA mir-432

disease_progression

mRNA:decreased expression:colon (human)

NCBI chr 8:69,106,415...69,106,501
Ensembl chr 8:69,106,415...69,106,501

G

matrix metallopeptidase 2

disease_progression

associated with Carcinoma, Ductal, Breast
associated with Tongue Neoplasms

PMID:23107277 PMID:23280016

RGD:8547824 RGD:8655998

NCBI chr 2:60,471,092...60,492,991
Ensembl chr 2:60,471,257...60,494,113

G

matrix metallopeptidase 3 (stromelysin 1, progelatinase)

associated with breast cancer;DNA:deletion:promoter:-1170_-1172delA (human)

NCBI chr 5:28,949,631...28,957,915
Ensembl chr 5:28,949,631...28,958,222

G

matrix metallopeptidase 9

disease_progression

associated with Endometrial Neoplasms;protein:increased expression:endometrium
associated with Tongue Neoplasms
associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum

PMID:12487935 PMID:20704821 PMID:23107277

RGD:2298523 RGD:5129215 RGD:8547824

NCBI chr24:33,274,260...33,281,116
Ensembl chr24:33,274,268...33,281,293

G

mutS homolog 2

associated with laryngeal squamous cell carcinoma

NCBI chr10:49,517,448...49,594,001
Ensembl chr10:49,517,369...49,594,210

G

metastasis associated 1

associated with Carcinoma, Non-Small-Cell Lung;mRNA:increased expression:lung

NCBI chr 8:72,752,894...72,772,236
Ensembl chr 8:72,753,178...72,772,762

G

mechanistic target of rapamycin kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:84,818,893...84,939,283
Ensembl chr 2:84,787,708...84,939,114

G

mucin 1, cell surface associated

associated with Common Bile Duct Neoplasms
associated with Esophageal Neoplasms
associated with Gallbladder Neoplasms;protein:altered localization:gallbladder
associated with Carcinoma, Renal Cell;

PMID:10390012 PMID:11295067 PMID:16222735 PMID:21339746

RGD:2324649 RGD:2324860 RGD:7245968 RGD:7349383

NCBI chr 7:42,338,939...42,344,690
Ensembl chr 7:42,340,375...42,344,690

G

mucin 5AC, oligomeric mucus/gel-forming

associated with chloangiocarcinoma;protein:increased expression:bile duct

NCBI chr18:45,471,232...45,498,961

G

neural cell adhesion molecule 1

NCBI chr 5:19,895,587...20,192,334
Ensembl chr 5:19,895,613...20,191,995

G

non-metastatic cells 1, protein (NM23A) expressed in

associated with Cervix Neoplasms; associated with Endometrial Neoplasms
associated with Breast Neoplasms

PMID:8102131 PMID:8855975 PMID:9036878

RGD:2299061 RGD:2299062 RGD:2299077

NCBI chr 9:26,990,336...26,998,895
Ensembl chr 9:26,990,469...26,998,955

G

non-metastatic cells 2, protein (NM23B) expressed in

associated with Cervix Neoplasms; associated with Endometrial Neoplasms

NCBI chr 9:27,002,114...27,005,740
Ensembl chr 9:27,001,733...27,015,934

G

nitric oxide synthase 3

susceptibility

associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human)

NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277

G

8-oxoguanine DNA glycosylase

associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human)

NCBI chr20:8,486,150...8,491,448
Ensembl chr20:8,480,005...8,491,264

G

PAXIP1 associated glutamate rich protein 1

disease_progression

protein:decreased expression:esophagus (human)

NCBI chr 6:17,876,740...17,879,546

G

platelet derived growth factor subunit A

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr 6:16,271,082...16,293,246
Ensembl chr 6:16,270,104...16,292,396

G

platelet derived growth factor subunit B

associated with Breast Neoplasms;mRNA:increased expression:lymph node

NCBI chr10:25,798,877...25,819,422
Ensembl chr10:25,798,938...25,817,746

G

3-phosphoinositide dependent protein kinase 1

associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum

NCBI chr 6:38,426,464...38,506,520
Ensembl chr 6:38,431,600...38,499,295

G

podoplanin

associated with Breast Neoplasms
associated with Cervix Neoplasms

PMID:16528371 PMID:18165897

RGD:2292231 RGD:2292237

NCBI chr 2:83,552,735...83,581,375
Ensembl chr 2:83,552,830...83,581,375

G

phosphatidylethanolamine binding protein 1

associated with Cervix Neoplasms
associated with Breast Neoplasms

PMID:16243812 PMID:18191186

RGD:2302867 RGD:2302868

NCBI chr26:14,522,124...14,526,370
Ensembl chr26:14,500,074...14,529,354

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

associated with Colorectal Neoplasms

NCBI chr34:12,600,140...12,681,905
Ensembl chr34:12,600,233...12,675,910

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta

associated with Colorectal Neoplasms

NCBI chr23:34,832,661...34,955,410
Ensembl chr23:34,836,540...34,993,939

G

phosphatidylinositol-4-phosphate 5-kinase type 1 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr17:60,257,017...60,295,866
Ensembl chr17:60,257,332...60,295,866

G

POU class 5 homeobox 1

associated with Seminoma; associated with Carcinoma, Embryonal

G

peroxisome proliferator activated receptor gamma

associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium

NCBI chr20:6,134,618...6,265,481
Ensembl chr20:6,050,357...6,207,981

G

phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1

associated with Prostatic Neoplasms

NCBI chr24:35,403,078...35,503,428
Ensembl chr24:35,404,564...35,582,041

G

phosphatase and tensin homolog

associated with Breast Neoplasms
associated with Prostatic Neoplasms;protein:decreased expression:prostate

PMID:17163422 PMID:17919877

RGD:2292499 RGD:2292507

NCBI chr26:37,853,148...37,913,176
Ensembl chr26:37,835,661...37,913,176

G

prostaglandin-endoperoxide synthase 2

associated with Breast Neoplasms
associated with Biliary Tract Neoplasms
associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human)

PMID:18159174 PMID:18353210 PMID:20016751

RGD:2300128 RGD:2317165 RGD:5135471

NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903

G

protein tyrosine kinase 2

associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node

NCBI chr13:35,302,439...35,541,336
Ensembl chr13:35,303,380...35,541,294

G

protein tyrosine phosphatase non-receptor type 13

associated with lung squamous cell carcinoma; protein:decreased expression:lymph node

NCBI chr32:10,125,447...10,328,764
Ensembl chr32:10,125,441...10,328,757

G

receptor activity modifying protein 2

disease_progression

associated with colorectal cancer; protein:increased expression:lymph node (human)

NCBI chr 9:20,250,711...20,252,485

G

receptor activity modifying protein 3

associated with colorectal cancer; protein:increased expression:lymph node (human)

G

Ras association domain family member 2

CTD Direct Evidence: marker/mechanism

NCBI chr24:16,736,786...16,779,910
Ensembl chr24:16,736,962...16,781,569

G

RNA binding motif protein 10

associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human)

NCBI chr X:40,746,959...40,776,764
Ensembl chr X:40,747,178...40,776,742

G

RELA proto-oncogene, NF-kB subunit

associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland

NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875

G

ret proto-oncogene

associated with Pancreatic Neoplasms

NCBI chr28:3,946,132...3,995,505
Ensembl chr28:3,947,232...3,994,210

G

ras homolog family member A

associated with Bladder Neoplasms;protein:increased expression:lymph node
associated with colorectal cancer

PMID:12855641 PMID:17597401

RGD:13432052 RGD:2298872

NCBI chr20:39,824,552...39,888,089
Ensembl chr20:39,824,575...39,887,215

G

RPTOR independent companion of MTOR complex 2

associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human)

NCBI chr 4:69,903,393...70,013,168
Ensembl chr 4:69,936,379...70,010,566

G

RUNX family transcription factor 1

associated with Carcinoid Tumor

NCBI chr31:30,170,859...30,420,344
Ensembl chr31:30,170,605...30,420,839

G

stratifin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:73,268,289...73,269,663
Ensembl chr 2:73,268,791...73,269,537

G

S-phase kinase associated protein 2

associated with Endometrial Neoplasms;protein:increased expression:endometrium

NCBI chr 4:72,352,966...72,386,469
Ensembl chr 4:72,352,986...72,386,307

G

solute carrier family 22 member 10

CTD Direct Evidence: marker/mechanism

NCBI chr18:53,597,148...53,628,569
Ensembl chr18:53,597,533...53,628,165

G

solute carrier family 7 member 5

severity

associated with gastric adenocarcinoma;protein:increased expression: :
associated with stomach carcinoma

PMID:21501294 PMID:25908107

RGD:11052781 RGD:151361203

NCBI chr 5:65,313,105...65,343,858
Ensembl chr 5:65,313,105...65,343,858

G

SMAD family member 4

associated with Breast Neoplasms

NCBI chr 1:23,875,989...23,930,027
Ensembl chr 1:23,882,139...23,969,405

G

smoothened, frizzled class receptor

associated with colorectal cancer

NCBI chr14:7,518,871...7,527,703
Ensembl chr14:7,518,856...7,528,033

G

synuclein gamma

NCBI chr 4:34,604,867...34,608,851
Ensembl chr 4:34,605,091...34,608,842

G

suppressor of cytokine signaling 2

associated with Prostatic Neoplasms

NCBI chr15:33,761,434...33,788,973
Ensembl chr15:33,785,545...33,877,869

G

suppressor of cytokine signaling 3

associated with Breast Neoplasms

NCBI chr 9:2,859,267...2,859,944

G

superoxide dismutase 2

disease_progression

CTD Direct Evidence: marker/mechanism
associated with tongue neoplasms;

PMID:10853026 PMID:19381893 PMID:20618948

NCBI chr 1:48,943,472...48,955,158
Ensembl chr 1:48,836,262...48,955,706

G

SRY-box transcription factor 2

disease_progression

associated with Breast Neoplasms

NCBI chr34:14,853,000...14,855,153

G

SRC proto-oncogene, non-receptor tyrosine kinase

associated with colon adenocarcinoma,

NCBI chr24:25,982,499...26,019,748
Ensembl chr24:25,999,048...26,018,077

G

ST14 transmembrane serine protease matriptase

associated with Endometrial Neoplasms

NCBI chr 5:4,652,493...4,666,728
Ensembl chr 5:4,651,863...4,691,069

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:20,539,660...20,614,631
Ensembl chr 9:20,539,697...20,612,672

G

serine/threonine kinase 11

associated with Breast Neoplasms;protein:decreased expression

NCBI chr20:57,558,966...57,579,163
Ensembl chr20:57,559,424...57,579,118

G

telomerase reverse transcriptase

disease_progression

associated with lung non-small cell carcinoma;

NCBI chr34:11,288,622...11,307,790
Ensembl chr34:11,288,622...11,307,951

G

TIMP metallopeptidase inhibitor 1

associated with Endometrial Neoplasms;protein:increased expression:endometrium

NCBI chr X:41,201,623...41,205,314
Ensembl chr X:41,201,638...41,205,310

G

TIMP metallopeptidase inhibitor 3

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr10:30,627,154...30,681,520
Ensembl chr10:30,627,154...30,694,288

G

TIMP metallopeptidase inhibitor 4

associated with Breast Neoplasms;mRNA:increased expression:breast

NCBI chr20:6,399,522...6,405,089
Ensembl chr20:6,399,522...6,405,089

G

toll like receptor 4

associated with Carcinoma, Ductal, Breast;

NCBI chr11:71,356,390...71,367,166
Ensembl chr11:71,356,390...71,367,165

G

tumor protein p53

associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P
associated with Penile Neoplasms
associated with Carcinoma, Squamous Cell;

PMID:18059331 PMID:18230179 PMID:18268397

RGD:2290533 RGD:2290534 RGD:8547790

NCBI chr 5:32,561,406...32,565,149
Ensembl chr 5:32,560,598...32,574,109

G

tumor protein p53 binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr30:10,263,650...10,362,646
Ensembl chr30:10,263,650...10,336,134

G

tRNA methyltransferase 11 homolog

CTD Direct Evidence: marker/mechanism

NCBI chr 1:64,861,404...64,917,449
Ensembl chr 1:64,834,770...65,064,562

G

TSC complex subunit 2

associated with Breast Neoplasms

NCBI chr 6:38,865,509...38,898,977
Ensembl chr 6:38,865,507...38,898,960

G

thyroid stimulating hormone receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:53,327,280...53,482,898
Ensembl chr 8:53,326,655...53,482,898

G

transthyretin

associated with colorectal cancer;protein:decreased expresion:blood serum (human)

NCBI chr 7:57,940,354...57,947,084
Ensembl chr 7:57,914,381...57,947,058

G

vascular endothelial growth factor A

associated with Breast neoplasms;
associated with Cervix Neoplasms

PMID:17597103 PMID:19783962

RGD:2315454 RGD:7421574

NCBI chr12:12,209,032...12,224,978
Ensembl chr12:12,208,231...12,224,965

G

vascular endothelial growth factor C

exacerbates
disease_progression

associated with Lymphatic Metastasis;
associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human)
associated with Breast Neoplasms
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder
associated with Prostatic Neoplasms
associated with thyroid diseases;mRNA:increased expression:thyroid gland:
associated with Cervix Neoplasms

PMID:12203051 PMID:15289890 PMID:17034609 PMID:18061373 PMID:19589137 More...

RGD:155630642 RGD:2315469 RGD:2315474 RGD:2315475 RGD:2315484 RGD:7483611 RGD:7488946

NCBI chr16:52,883,242...52,987,684
Ensembl chr16:52,883,139...52,987,563

G

vascular endothelial growth factor D

associated with Breast Neoplasms
associated with Cervix Neoplasms

PMID:17951197 PMID:19589137

RGD:2315475 RGD:2315480

NCBI chr X:11,590,097...11,627,199
Ensembl chr X:11,590,089...11,626,486

G

WD repeat containing antisense to TP53

associated with esophagus squamous cell carcinoma;
associated with lung non-small cell carcinoma;

PMID:24626331 PMID:31281482

RGD:21081513 RGD:21081532

NCBI chr 5:32,574,153...32,586,222
Ensembl chr 5:32,574,134...32,594,333

Neoplasm Invasiveness

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:49,699,072...49,758,783
Ensembl chr11:49,699,109...49,923,257

G

actin beta

CTD Direct Evidence: marker/mechanism

NCBI chr 6:12,421,006...12,424,449
Ensembl chr 6:12,418,932...12,462,845

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

CTD Direct Evidence: marker/mechanism

NCBI chr31:22,169,821...22,178,879
Ensembl chr31:22,170,381...22,178,945

G

AHNAK nucleoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr18:54,085,186...54,116,011
Ensembl chr18:54,100,942...54,113,424

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

PMID:25826687 PMID:27752740

NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

NCBI chr 6:18,077,241...18,083,053

G

alkB homolog 8, tRNA methyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:24,843,145...24,897,906
Ensembl chr 5:24,833,373...25,080,451

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr28:2,170,920...2,218,765
Ensembl chr28:2,170,920...2,219,609

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: therapeutic

NCBI chr11:68,338,644...68,353,366
Ensembl chr11:68,338,389...68,351,994

G

angiomotin like 1

CTD Direct Evidence: marker/mechanism

NCBI chr21:6,109,600...6,280,025
Ensembl chr21:6,109,683...6,256,060

G

angiopoietin 1

associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland

NCBI chr13:8,068,920...8,312,090
Ensembl chr13:8,048,205...8,311,618

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr20:52,942,090...52,948,126
Ensembl chr20:52,942,259...52,947,475

G

annexin A1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011

G

annexin A2

CTD Direct Evidence: marker/mechanism

NCBI chr30:25,176,845...25,210,244
Ensembl chr30:25,115,842...25,218,281

G

ARF GTPase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:835,476...836,424
Ensembl chr14:835,476...836,424

G

AXL receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:112,699,679...112,727,434
Ensembl chr 1:112,700,365...112,726,960

G

B9 domain containing 2

CTD Direct Evidence: marker/mechanism

PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 More...

NCBI chr 1:112,621,832...112,627,726
Ensembl chr 1:112,621,633...112,643,885

G

BCAR1 scaffold protein, Cas family member

CTD Direct Evidence: marker/mechanism

NCBI chr 5:75,463,906...75,499,557
Ensembl chr 5:75,463,926...75,512,476

G

BRMS1 transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr18:50,967,175...50,974,816
Ensembl chr18:50,967,270...50,974,321

G

basigin

CTD Direct Evidence: marker/mechanism

NCBI chr20:57,942,703...57,951,089
Ensembl chr20:57,943,276...57,951,061

G

calreticulin

CTD Direct Evidence: marker/mechanism

NCBI chr20:49,251,390...49,255,291
Ensembl chr20:49,251,777...49,255,245

G

calumenin

CTD Direct Evidence: marker/mechanism

NCBI chr14:7,869,946...7,899,302
Ensembl chr14:7,872,076...7,925,078

G

catalase

CTD Direct Evidence: therapeutic

PMID:21749277 PMID:22580338

NCBI chr18:33,383,005...33,422,447
Ensembl chr18:33,383,005...33,422,447

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

PMID:25199511 PMID:32512068

NCBI chr 9:39,008,187...39,009,932

G

C-C motif chemokine ligand 5

CTD Direct Evidence: marker/mechanism

NCBI chr 9:37,817,409...37,823,852
Ensembl chr 9:37,817,305...37,823,852

G

CD82 molecule

CTD Direct Evidence: therapeutic

NCBI chr18:44,658,414...44,707,897
Ensembl chr18:44,659,180...44,706,768

G

cadherin 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:19839049 PMID:22580338

NCBI chr 5:80,757,508...80,834,878
Ensembl chr 5:80,757,508...80,834,878

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:60,736,760...60,950,477
Ensembl chr 7:60,736,760...60,951,034

G

cyclin dependent kinase inhibitor 2A

CTD Direct Evidence: marker/mechanism

NCBI chr11:41,223,316...41,226,056
Ensembl chr11:41,223,315...41,264,379

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:51,404,649...51,408,240
Ensembl chr18:51,401,659...51,408,212

G

chitinase 3 like 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:25,620...32,954
Ensembl chr 7:26,316...33,427

G

cholinergic receptor nicotinic alpha 7 subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,852,082...37,164,930
Ensembl chr 3:36,852,543...36,978,399

G

chromosome segregation 1 like

CTD Direct Evidence: marker/mechanism

NCBI chr24:35,759,556...35,806,090
Ensembl chr24:35,759,598...35,805,769

G

cystatin B

CTD Direct Evidence: marker/mechanism

PMID:19747051 PMID:22287159

G

C-terminal binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr28:34,259,912...34,415,113
Ensembl chr28:34,260,856...34,415,696

G

catenin beta 1

CTD Direct Evidence: marker/mechanism

PMID:23707762 PMID:26990689

NCBI chr23:10,559,722...10,572,933
Ensembl chr23:10,559,718...10,572,927

G

cathepsin B

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:19747051

NCBI chr25:26,048,237...26,056,570
Ensembl chr25:26,048,253...26,055,801

G

cathepsin D

CTD Direct Evidence: marker/mechanism

NCBI chr18:46,010,440...46,019,457
Ensembl chr18:46,010,440...46,019,457

G

cathepsin S

CTD Direct Evidence: marker/mechanism

NCBI chr17:59,893,840...59,910,878
Ensembl chr17:59,893,840...59,910,849

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,795,273...105,800,722

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:64,640,389...64,647,298
Ensembl chr 5:64,640,389...64,647,215

G

C-X-C motif chemokine ligand 12

CTD Direct Evidence: marker/mechanism

PMID:19700239 PMID:25231984 PMID:25753200

NCBI chr28:2,895,916...2,903,543

G

C-X-C motif chemokine ligand 8

CTD Direct Evidence: marker/mechanism

NCBI chr13:62,435,035...62,438,354
Ensembl chr13:62,434,422...62,438,354

G

C-X-C motif chemokine receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

cytochrome P450 family 2 subfamily E member 1

CTD Direct Evidence: marker/mechanism

NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

PMID:21291860 PMID:27811057

NCBI chr35:17,014,802...17,045,308
Ensembl chr35:17,016,231...17,044,749

G

distal-less homeobox 4

CTD Direct Evidence: marker/mechanism

NCBI chr 9:26,001,287...26,002,708
Ensembl chr 9:25,976,680...26,002,323

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:26,290,903...28,444,635
Ensembl chr X:26,290,910...28,333,576

G

DNA methyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:50,872,213...50,928,352
Ensembl chr20:50,879,527...50,928,029

G

endothelin receptor type B

CTD Direct Evidence: marker/mechanism

NCBI chr22:31,415,324...31,438,772
Ensembl chr22:31,417,308...31,437,587

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:55,577,413...55,586,422
Ensembl chr20:55,522,213...55,586,126

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:15802018 PMID:22869556 PMID:23064031 PMID:24587105 PMID:27634460

NCBI chr32:30,073,541...30,166,904
Ensembl chr32:30,073,950...30,166,295

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:23867902

NCBI chr18:5,983,669...6,044,092
Ensembl chr18:5,982,770...6,042,631

G

eukaryotic translation initiation factor 4E

CTD Direct Evidence: marker/mechanism

NCBI chr32:21,064,202...21,108,998
Ensembl chr32:21,065,270...21,124,483

G

elongator acetyltransferase complex subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:64,035,667...64,094,402
Ensembl chr11:64,037,506...64,093,819

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr25:29,415,229...29,507,159
Ensembl chr25:29,415,924...29,507,098

G

engrailed homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:31,124,325...31,129,538

G

enolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:62,300,805...62,314,508
Ensembl chr 5:62,300,808...62,304,093

G

endothelial PAS domain protein 1

CTD Direct Evidence: marker/mechanism

PMID:26735578 PMID:30090327

NCBI chr10:48,550,836...48,636,776
Ensembl chr10:48,551,410...48,634,844

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr 6:8,994,211...8,995,954
Ensembl chr 6:8,994,211...8,996,144

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:49,945,777...49,950,856
Ensembl chr20:49,945,777...49,950,856

G

EGFR pathway substrate 8, signaling adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr27:30,893,884...31,070,401
Ensembl chr27:30,893,713...31,069,770

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:26990689 PMID:27366082 PMID:35044086

NCBI chr 1:42,081,952...42,368,544
Ensembl chr 1:42,081,969...42,368,544

G

family with sequence similarity 83 member A

CTD Direct Evidence: marker/mechanism

NCBI chr13:21,566,083...21,590,291
Ensembl chr13:21,566,059...21,589,976

G

fibroblast growth factor receptor 4

ClinVar Annotator: match by term: Cancer progression and tumor cell motility

PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287

NCBI chr 4:36,243,689...36,254,636
Ensembl chr 4:36,244,220...36,252,035

G

fibronectin 1

CTD Direct Evidence: marker/mechanism

NCBI chr37:22,456,854...22,522,410
Ensembl chr37:22,420,428...22,523,123

G

forkhead box P1

CTD Direct Evidence: marker/mechanism

NCBI chr20:20,438,631...21,020,516
Ensembl chr20:20,788,433...21,016,397

G

ferritin heavy chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:54,466,167...54,468,733
Ensembl chr18:54,466,023...54,468,732

G

ferritin light chain

CTD Direct Evidence: marker/mechanism

NCBI chr 1:107,418,457...107,419,923
Ensembl chr 1:107,418,458...107,419,923

G

GRB2 associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr21:20,414,903...20,605,807
Ensembl chr21:20,277,507...20,606,736

G

histone deacetylase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:36,583,283...36,598,121
Ensembl chr 2:36,583,283...36,597,682

G

hepatocyte growth factor

CTD Direct Evidence: marker/mechanism

PMID:9932610 PMID:15654357

NCBI chr18:21,329,688...21,410,257
Ensembl chr18:21,332,817...21,410,263

G

hypoxia inducible factor 1 subunit alpha

CTD Direct Evidence: marker/mechanism

PMID:12811834 PMID:29501572

NCBI chr 8:36,614,045...36,656,692
Ensembl chr 8:36,614,045...36,656,692

G

high mobility group AT-hook 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:8,348,101...8,491,435

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:56,679,942...56,698,521
Ensembl chr17:56,680,301...56,698,419

G

heme oxygenase 1

CTD Direct Evidence: therapeutic

NCBI chr10:28,744,404...28,751,544
Ensembl chr10:28,743,795...28,751,773

G

homeobox B13

CTD Direct Evidence: marker/mechanism

NCBI chr 9:24,958,020...24,961,353
Ensembl chr 9:24,959,183...24,961,588

G

homeobox B3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:24,810,299...24,837,434
Ensembl chr 9:24,809,739...24,836,058

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr32:7,166,437...7,199,659
Ensembl chr32:7,167,856...7,199,665

G

HRas proto-oncogene, GTPase

CTD Direct Evidence: marker/mechanism

NCBI chr18:25,642,844...25,644,717
Ensembl chr18:25,642,844...25,644,717

G

inhibitor of DNA binding 4, HLH protein

CTD Direct Evidence: marker/mechanism

NCBI chr35:18,358,518...18,360,767
Ensembl chr35:18,357,826...18,359,011
Ensembl chr35:18,357,826...18,359,011

G

insulin like growth factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr15:41,203,320...41,275,964
Ensembl chr15:41,202,518...41,275,794

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458

G

interleukin 1 receptor antagonist

CTD Direct Evidence: therapeutic

NCBI chr17:37,236,690...37,250,424
Ensembl chr17:37,212,751...37,249,329

G

interleukin 6

CTD Direct Evidence: marker/mechanism

PMID:26101800 PMID:26284488

NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519

G

insulin

CTD Direct Evidence: marker/mechanism

NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122

G

iron responsive element binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:38,398,445...38,441,128
Ensembl chr13:38,400,591...38,441,015

G

integrin subunit alpha 5

CTD Direct Evidence: marker/mechanism

NCBI chr27:904,892...924,757
Ensembl chr27:904,102...924,084

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:3,728,472...3,757,696
Ensembl chr 2:3,670,596...3,756,961

G

inositol-tetrakisphosphate 1-kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:1,976,089...2,136,228
Ensembl chr 8:1,977,740...2,136,339

G

potassium voltage-gated channel subfamily D member 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:58,441,274...58,915,512

G

lysine demethylase 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 2:76,313,742...76,375,716
Ensembl chr 2:76,156,434...76,375,632

G

keratin 19

CTD Direct Evidence: marker/mechanism

NCBI chr 9:21,240,778...21,245,039

G

keratin 7

CTD Direct Evidence: marker/mechanism

NCBI chr27:2,812,709...2,827,451

G

lactate dehydrogenase B

CTD Direct Evidence: marker/mechanism

NCBI chr27:25,470,666...25,493,114
Ensembl chr27:25,470,665...25,492,920

G

lymphoid enhancer binding factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr32:28,516,002...28,633,759
Ensembl chr32:28,517,108...28,634,019

G

lin-28 homolog A

CTD Direct Evidence: marker/mechanism

NCBI chr 2:73,638,438...73,656,841
Ensembl chr 2:73,614,531...73,628,211
Ensembl chr 2:73,614,531...73,628,211

G

thioredoxin-like

CTD Direct Evidence: marker/mechanism

NCBI chr X:82,986,288...82,986,753

G

glycine-rich cell wall structural protein 1-like

CTD Direct Evidence: marker/mechanism

NCBI chr 6:38,183,097...38,194,899

G

serotransferrin

CTD Direct Evidence: marker/mechanism

NCBI chr23:30,658,250...30,683,816
Ensembl chr23:30,595,704...30,683,845

G

chemokine (C-C motif) ligand 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:37,708,561...37,710,209
Ensembl chr 9:37,676,966...37,710,209

G

lysyl oxidase like 2

CTD Direct Evidence: marker/mechanism

NCBI chr25:34,095,858...34,186,775
Ensembl chr25:34,126,335...34,185,969

G

mitogen-activated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998

G

mitogen-activated protein kinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425

G

MET proto-oncogene, receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr14:55,599,047...55,711,626
Ensembl chr14:55,598,337...55,724,027

G

microRNA mir-155

CTD Direct Evidence: marker/mechanism

NCBI chr31:21,078,768...21,078,828
Ensembl chr31:21,078,758...21,078,833

G

microRNA mir-186

CTD Direct Evidence: marker/mechanism

NCBI chr 6:74,881,615...74,881,675
Ensembl chr 6:74,881,601...74,881,686

G

microRNA mir-191

CTD Direct Evidence: marker/mechanism

NCBI chr20:40,144,135...40,144,198
Ensembl chr20:40,144,121...40,144,210

G

microRNA mir-200b

CTD Direct Evidence: therapeutic

NCBI chr 5:56,368,400...56,368,479
Ensembl chr 5:56,368,400...56,368,479

G

microRNA mir-200c

CTD Direct Evidence: therapeutic

NCBI chr27:38,082,097...38,082,159
Ensembl chr27:38,082,091...38,082,169

G

microRNA mir-21

CTD Direct Evidence: marker/mechanism

PMID:26101800 PMID:29501572

NCBI chr 9:34,340,550...34,340,609
Ensembl chr 9:34,340,533...34,340,624

G

microRNA mir-217

CTD Direct Evidence: marker/mechanism

NCBI chr10:56,754,566...56,754,647
Ensembl chr10:56,754,566...56,754,647

G

microRNA mir-346

CTD Direct Evidence: marker/mechanism

PMID:27501413 PMID:27777383

NCBI chr 4:34,073,335...34,073,429
Ensembl chr 4:34,073,335...34,073,429

G

microRNA mir-497

CTD Direct Evidence: marker/mechanism

NCBI chr 5:32,045,759...32,045,825
Ensembl chr 5:32,045,759...32,045,825

G

microRNA mir-532

CTD Direct Evidence: marker/mechanism

NCBI chr X:42,774,680...42,774,738
Ensembl chr X:42,774,680...42,774,738

G

microRNA mir-543

CTD Direct Evidence: therapeutic

NCBI chr 8:69,263,406...69,263,463

G

microRNA mir-708

CTD Direct Evidence: therapeutic

NCBI chr21:19,542,577...19,542,645
Ensembl chr21:19,542,577...19,542,645

G

microRNA mir-874

CTD Direct Evidence: therapeutic

NCBI chr11:25,355,355...25,355,432
Ensembl chr11:25,355,354...25,355,437

G

matrix metallopeptidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:28,978,385...28,986,644
Ensembl chr 5:28,978,473...28,986,648

G

matrix metallopeptidase 14

CTD Direct Evidence: marker/mechanism

NCBI chr 8:3,183,419...3,193,079
Ensembl chr 8:3,183,606...3,194,122

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709

NCBI chr 2:60,471,092...60,492,991
Ensembl chr 2:60,471,257...60,494,113

G

matrix metallopeptidase 3 (stromelysin 1, progelatinase)

CTD Direct Evidence: marker/mechanism

PMID:20188714 PMID:26284488

NCBI chr 5:28,949,631...28,957,915
Ensembl chr 5:28,949,631...28,958,222

G

matrix metallopeptidase 9

CTD Direct Evidence: marker/mechanism

PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 More...

NCBI chr24:33,274,260...33,281,116
Ensembl chr24:33,274,268...33,281,293

G

transcription initiation factor TFIID subunit 4

CTD Direct Evidence: marker/mechanism

NCBI chr 2:59,624,845...59,630,386

G

metallothionein 1H

CTD Direct Evidence: marker/mechanism

NCBI chr 2:59,607,926...59,608,825
Ensembl chr 2:59,607,927...59,626,727

G

metadherin

CTD Direct Evidence: marker/mechanism

NCBI chr29:41,675,601...41,732,389
Ensembl chr29:41,640,035...41,729,949

G

MYD88 innate immune signal transduction adaptor

CTD Direct Evidence: marker/mechanism

NCBI chr23:7,901,578...7,905,274
Ensembl chr23:7,901,250...7,904,534

G

myosin heavy chain 9

CTD Direct Evidence: marker/mechanism

NCBI chr10:28,063,626...28,122,953
Ensembl chr10:28,063,624...28,122,953

G

myosin light chain kinase

CTD Direct Evidence: marker/mechanism

PMID:10232591 PMID:12970723

NCBI chr33:26,663,991...26,867,370
Ensembl chr33:26,664,800...26,843,181

G

neural cell adhesion molecule 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:19,895,587...20,192,334
Ensembl chr 5:19,895,613...20,191,995

G

NIMA related kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:10,039,617...10,052,511
Ensembl chr 7:10,040,187...10,052,512

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr36:20,989,205...21,087,044
Ensembl chr36:20,989,360...21,012,524

G

non-metastatic cells 1, protein (NM23A) expressed in

CTD Direct Evidence: marker/mechanism

NCBI chr 9:26,990,336...26,998,895
Ensembl chr 9:26,990,469...26,998,955

G

notch receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:56,854,825...57,020,157
Ensembl chr17:56,860,429...57,020,857

G

neuregulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:31,697,958...32,771,888
Ensembl chr16:31,706,851...32,771,932

G

NUAK family kinase 1

CTD Direct Evidence: marker/mechanism

PMID:26213588 PMID:26873845

NCBI chr10:32,463,845...32,537,425
Ensembl chr10:32,464,123...32,536,650

G

p21 (RAC1) activated kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr21:21,341,530...21,409,535
Ensembl chr21:21,265,484...21,408,416

G

paired box 6

CTD Direct Evidence: marker/mechanism

G

programmed cell death 4

CTD Direct Evidence: marker/mechanism

NCBI chr28:22,198,274...22,227,184
Ensembl chr28:22,198,322...22,226,717

G

phosphatidylinositol-4-phosphate 5-kinase type 1 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr17:60,257,017...60,295,866
Ensembl chr17:60,257,332...60,295,866

G

pyruvate kinase M1/2

CTD Direct Evidence: marker/mechanism

PMID:15048980 PMID:15654357

NCBI chr30:35,712,853...35,737,643

G

plasminogen activator, urokinase

CTD Direct Evidence: marker/mechanism

PMID:14644129 PMID:26284488

NCBI chr 4:24,329,139...24,333,893
Ensembl chr 4:24,328,925...24,334,851

G

plasminogen activator, urokinase receptor

CTD Direct Evidence: marker/mechanism

PMID:12198772 PMID:22261521

NCBI chr 1:111,476,804...111,490,876
Ensembl chr 1:111,476,893...111,490,880

G

protein phosphatase 1 regulatory subunit 12B

CTD Direct Evidence: marker/mechanism

NCBI chr 7:512,692...713,848
Ensembl chr 7:512,575...713,709

G

peroxiredoxin 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:49,352,271...49,356,755
Ensembl chr20:49,352,266...49,356,682

G

phosphatase and tensin homolog

CTD Direct Evidence: therapeutic

NCBI chr26:37,853,148...37,913,176
Ensembl chr26:37,835,661...37,913,176

G

protein tyrosine kinase 2

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:12811834 PMID:25199511

NCBI chr13:35,302,439...35,541,336
Ensembl chr13:35,303,380...35,541,294

G

RAB27A, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr30:20,633,576...20,706,240
Ensembl chr30:20,635,400...20,690,521

G

RAB27B, member RAS oncogene family

CTD Direct Evidence: marker/mechanism

NCBI chr 1:20,695,100...20,832,745
Ensembl chr 1:20,700,514...20,832,975

G

RAS protein activator like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:21,243,984...21,591,932
Ensembl chr 7:21,222,089...21,591,973

G

RNA binding motif protein 38

CTD Direct Evidence: therapeutic

NCBI chr24:42,396,356...42,410,543
Ensembl chr24:42,396,352...42,409,240

G

reversion inducing cysteine rich protein with kazal motifs

CTD Direct Evidence: therapeutic

NCBI chr11:52,519,303...52,607,753
Ensembl chr11:52,519,317...52,607,217

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

PMID:19896475 PMID:29501572

NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875

G

ras homolog family member A

CTD Direct Evidence: marker/mechanism

NCBI chr20:39,824,552...39,888,089
Ensembl chr20:39,824,575...39,887,215

G

ring finger protein 207

CTD Direct Evidence: marker/mechanism

NCBI chr 5:60,105,200...60,119,902
Ensembl chr 5:60,106,297...60,118,670

G

ribosomal protein L3 like

CTD Direct Evidence: marker/mechanism

NCBI chr 6:38,971,098...38,981,466
Ensembl chr 6:38,974,018...38,982,012

G

ribosomal protein S6 kinase A3

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,991,623...16,079,689
Ensembl chr X:15,998,172...16,074,749

G

ribosomal protein SA

CTD Direct Evidence: marker/mechanism

NCBI chr23:9,070,953...9,077,058
Ensembl chr23:9,070,953...9,077,057

G

S100 calcium binding protein A11

CTD Direct Evidence: marker/mechanism

NCBI chr17:61,020,136...61,050,513

G

S100 calcium binding protein A4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:43,494,007...43,496,021

G

sphingosine-1-phosphate receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:50,855,505...50,862,985
Ensembl chr20:50,860,591...50,861,649

G

septin 9

CTD Direct Evidence: marker/mechanism

NCBI chr 9:3,495,764...3,571,755
Ensembl chr 9:3,448,793...3,616,732

G

SET nuclear proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 9:54,896,464...54,907,698

G

solute carrier family 39 member 10

CTD Direct Evidence: marker/mechanism

NCBI chr37:5,482,200...5,521,104
Ensembl chr37:5,482,177...5,521,110

G

solute carrier family 6 member 12

CTD Direct Evidence: marker/mechanism

NCBI chr27:42,270,427...42,301,874
Ensembl chr27:42,270,448...42,336,464

G

sphingomyelin phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr21:29,714,418...29,719,035
Ensembl chr21:29,714,557...29,719,033

G

snail family transcriptional repressor 1

CTD Direct Evidence: marker/mechanism

PMID:22580338 PMID:24014025

NCBI chr24:36,498,343...36,503,623
Ensembl chr24:36,498,062...36,503,628

G

snail family transcriptional repressor 2

CTD Direct Evidence: marker/mechanism

NCBI chr29:1,154,132...1,156,653
Ensembl chr29:1,154,036...1,156,653

G

superoxide dismutase 2

CTD Direct Evidence: marker/mechanism

PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 More...

NCBI chr 1:48,943,472...48,955,158
Ensembl chr 1:48,836,262...48,955,706

G

sortilin related receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:12,493,750...12,650,530
Ensembl chr 5:12,431,377...12,650,784

G

SRY-box transcription factor 11

CTD Direct Evidence: marker/mechanism

G

SRY-box transcription factor 9

CTD Direct Evidence: marker/mechanism

NCBI chr 9:8,275,049...8,278,172
Ensembl chr 9:8,275,049...8,278,172

G

Sp1 transcription factor

CTD Direct Evidence: marker/mechanism

PMID:26317792 PMID:35072892

NCBI chr27:1,802,587...1,861,187
Ensembl chr27:1,805,184...1,847,226

G

SRC proto-oncogene, non-receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:18844224 PMID:21291860

NCBI chr24:25,982,499...26,019,748
Ensembl chr24:25,999,048...26,018,077

G

signal transducer and activator of transcription 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:20,539,660...20,614,631
Ensembl chr 9:20,539,697...20,612,672

G

small ubiquitin like modifier 1

CTD Direct Evidence: marker/mechanism

NCBI chr37:11,199,937...11,229,743
Ensembl chr37:11,200,590...11,229,754

G

T-box transcription factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr17:56,079,739...56,190,417
Ensembl chr17:56,081,411...56,204,192

G

tissue factor pathway inhibitor 2

NCBI chr14:19,399,259...19,403,890
Ensembl chr14:19,399,720...19,403,708

G

TGFB induced factor homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:70,040,376...70,048,346
Ensembl chr 7:70,040,508...70,047,912

G

TIMP metallopeptidase inhibitor 1

CTD Direct Evidence: therapeutic

NCBI chr X:41,201,623...41,205,314
Ensembl chr X:41,201,638...41,205,310

G

TIMP metallopeptidase inhibitor 3

CTD Direct Evidence: therapeutic

NCBI chr10:30,627,154...30,681,520
Ensembl chr10:30,627,154...30,694,288

G

transketolase

CTD Direct Evidence: marker/mechanism

NCBI chr20:36,690,540...36,705,980
Ensembl chr20:36,681,531...36,742,199

G

talin 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:52,227,286...52,260,112
Ensembl chr11:52,227,611...52,259,915

G

toll like receptor 4

CTD Direct Evidence: marker/mechanism

NCBI chr11:71,356,390...71,367,166
Ensembl chr11:71,356,390...71,367,165

G

transmembrane protein 139

CTD Direct Evidence: marker/mechanism

NCBI chr16:6,397,507...6,401,385
Ensembl chr16:6,380,778...6,399,579

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819

NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425

G

tumor protein p53 binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:40,296,278...40,329,818
Ensembl chr 7:40,252,697...40,329,828

G

tripartite motif containing 47

CTD Direct Evidence: marker/mechanism

NCBI chr 9:4,718,806...4,731,121
Ensembl chr 9:4,726,249...4,730,790

G

transient receptor potential cation channel subfamily M member 7

CTD Direct Evidence: marker/mechanism

NCBI chr30:16,465,546...16,579,874
Ensembl chr30:16,466,234...16,579,594

G

twist family bHLH transcription factor 1

CTD Direct Evidence: marker/mechanism

G

ubiquilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:75,767,345...75,812,278
Ensembl chr 1:75,767,188...75,838,051

G

vimentin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:19,671,316...19,679,367
Ensembl chr 2:19,671,316...19,679,466

G

XPC complex subunit, DNA damage recognition and repair factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,299,644...4,328,826
Ensembl chr20:4,300,386...4,328,768

G

X-ray repair cross complementing 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:71,441,732...71,452,922
Ensembl chr 8:71,442,429...71,449,408

G

Yes1 associated transcriptional regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 5:29,394,760...29,495,977
Ensembl chr 5:29,394,541...29,496,251

G

zinc finger and BTB domain containing 16

CTD Direct Evidence: marker/mechanism

NCBI chr 5:19,082,594...19,284,360
Ensembl chr 5:19,087,154...19,267,628

G

zinc finger E-box binding homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:15,300,401...15,481,535
Ensembl chr 2:15,299,723...15,481,495

G

zinc finger E-box binding homeobox 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:46,419,812...46,541,888
Ensembl chr19:46,423,998...46,542,122

G

ZFP36 ring finger protein

CTD Direct Evidence: therapeutic

NCBI chr 1:113,815,972...113,818,093
Ensembl chr 1:113,816,273...113,818,065

G

zinc finger RNA binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 4:75,038,248...75,124,154
Ensembl chr 4:74,982,467...75,123,053

G

zinc finger protein 367

CTD Direct Evidence: marker/mechanism

NCBI chr 1:70,461,631...70,485,380
Ensembl chr 1:70,461,776...70,483,053

Neoplasm Metastasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727

G

ATP binding cassette subfamily C member 4

CTD Direct Evidence: marker/mechanism

NCBI chr22:45,767,033...46,013,577
Ensembl chr22:45,765,835...46,013,505

G

angiotensin I converting enzyme

CTD Direct Evidence: marker/mechanism

NCBI chr 9:11,497,182...11,516,362
Ensembl chr 9:11,497,182...11,516,358

G

atypical chemokine receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr25:47,327,921...47,339,632
Ensembl chr25:47,327,963...47,339,622

G

acyl-CoA synthetase bubblegum family member 1

associated with pheochromocytoma

NCBI chr 3:58,319,222...58,367,087
Ensembl chr 3:58,319,376...58,366,854

G

activin A receptor type 2A

exacerbates

associated with colon cancer;mRNA,protein:decreased expression:colon (human)

NCBI chr19:49,642,429...49,726,720
Ensembl chr19:49,641,219...49,723,420

G

adhesion G protein-coupled receptor B1

associated with colorectal cancer

NCBI chr13:36,627,791...36,649,013
Ensembl chr13:36,614,498...36,690,936

G

adenosine A2b receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 5:39,884,375...39,908,214

G

angiotensin II receptor type 1

CTD Direct Evidence: marker/mechanism

NCBI chr23:43,569,658...43,617,113
Ensembl chr23:43,614,035...43,616,238

G

angiotensin II receptor type 2

CTD Direct Evidence: marker/mechanism

NCBI chr X:88,703,551...88,708,451
Ensembl chr X:88,705,765...88,706,853

G

aryl hydrocarbon receptor

CTD Direct Evidence: therapeutic

NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444

G

akirin 2

NCBI chr12:47,113,856...47,132,800
Ensembl chr12:47,113,857...47,132,555

G

AKT serine/threonine kinase 2

associated with Mammary Neoplasms, Experimental

NCBI chr 1:113,359,038...113,407,119
Ensembl chr 1:113,359,575...113,407,131

G

aldolase, fructose-bisphosphate A

CTD Direct Evidence: marker/mechanism

NCBI chr 6:18,077,241...18,083,053

G

ALK receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr17:23,010,308...23,688,841
Ensembl chr17:23,010,308...23,688,841

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr28:2,170,920...2,218,765
Ensembl chr28:2,170,920...2,219,609

G

adhesion molecule with Ig like domain 2

Liver Metastasis

NCBI chr27:7,507,426...7,510,015
Ensembl chr27:7,507,489...7,509,054

G

angiopoietin like 4

CTD Direct Evidence: therapeutic

NCBI chr20:52,942,090...52,948,126
Ensembl chr20:52,942,259...52,947,475

G

ANTXR cell adhesion molecule 1

associated with Mammary Neoplasms, Experimental;

NCBI chr10:67,829,573...68,021,368
Ensembl chr10:67,829,225...68,019,127

G

annexin A1

treatment

associated with Mammary Neoplasms, Experimental
associated with Mammary Neoplasms, Experimental;protein:increased expression:lung
CTD Direct Evidence: marker/mechanism

PMID:9514092 PMID:20308542 PMID:20821804

RGD:2306939 RGD:7421541 RGD:7421563

NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011

G

annexin A4

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,418,678...68,466,181
Ensembl chr10:68,431,056...68,466,174

G

annexin A7

associated with Breast Neoplasms;protein:increased expression:breast
associated with Prostatic Neoplasms;protein:decreased expression:prostate gland

PMID:11287641 PMID:15073110

RGD:2292655 RGD:2292656

NCBI chr 4:23,933,959...23,961,968
Ensembl chr 4:23,934,234...23,961,880

G

apolipoprotein E

NCBI chr 1:110,525,717...110,528,534
Ensembl chr 1:110,525,722...110,528,440

G

Rho GDP dissociation inhibitor alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 9:419,350...422,284
Ensembl chr 9:419,413...423,252

G

AT-rich interaction domain 1A

disease_progression

in lung; associated with hepatocellular carcinoma

NCBI chr 2:73,331,606...73,401,151
Ensembl chr 2:73,324,852...73,401,102

G

ATPase H+ transporting V1 subunit C1

associated with Mammary Neoplasms, Experimental

NCBI chr13:4,509,699...4,569,500
Ensembl chr13:4,510,003...4,579,846

G

AXL receptor tyrosine kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:112,699,679...112,727,434
Ensembl chr 1:112,700,365...112,726,960

G

antizyme inhibitor 1

associated with stomach cancer;RNA:increased editing:stomach
associated with colorectal cancer;RNA:increased editing:colorectum

PMID:29925690 PMID:30563560

RGD:14700703 RGD:14700704

NCBI chr13:4,363,996...4,396,069
Ensembl chr13:4,361,340...4,396,040

G

B9 domain containing 2

CTD Direct Evidence: marker/mechanism

PMID:23146760 PMID:23992306 PMID:26896736 PMID:31381904

NCBI chr 1:112,621,832...112,627,726
Ensembl chr 1:112,621,633...112,643,885

G

BCL2 associated X, apoptosis regulator

associated with Carcinoma, Infiltrating Duct

NCBI chr 1:107,423,388...107,426,464
Ensembl chr 1:107,422,424...107,426,464

G

BCL2 apoptosis regulator

associated with Carcinoma, Renal Cell
associated with Breast Neoplasms

PMID:12810203 PMID:16826579

RGD:2293020 RGD:2293021

NCBI chr 1:13,733,849...13,900,653
Ensembl chr 1:13,731,406...13,900,658

G

bone morphogenetic protein 6

severity

associated with Prostatic Neoplasms;protein:increased expression:bone

NCBI chr35:7,780,763...7,833,095
Ensembl chr35:7,804,231...7,831,845

G

bone morphogenetic protein 7

disease_progression

associated with Prostatic Neoplasms;mRNA:increased expression:bone
associated with Breast Neoplasms;protein:increased expression:breast

PMID:12539225 PMID:17895257

RGD:2289029 RGD:2289033

NCBI chr24:42,203,183...42,294,105
Ensembl chr24:42,204,823...42,294,653

G

B-Raf proto-oncogene, serine/threonine kinase

onset

associated with Melanoma; DNA:mutations: :

NCBI chr16:8,222,909...8,318,179
Ensembl chr16:8,222,907...8,317,906

G

bromodomain containing 4

NCBI chr20:46,844,795...46,927,620
Ensembl chr20:46,891,514...46,927,608

G

BRMS1 transcriptional repressor and anoikis regulator

CTD Direct Evidence: therapeutic

NCBI chr18:50,967,175...50,974,816
Ensembl chr18:50,967,270...50,974,321

G

basigin

CTD Direct Evidence: marker/mechanism

NCBI chr20:57,942,703...57,951,089
Ensembl chr20:57,943,276...57,951,061

G

calcium binding protein 39

associated with hepatocellular carcinoma;

NCBI chr25:42,752,798...42,801,257
Ensembl chr25:42,703,332...42,799,279

G

calcyclin binding protein

associated with pancreatic neoplasms

NCBI chr 7:24,372,599...24,384,084
Ensembl chr 7:24,372,596...24,383,926

G

cyclase associated actin cytoskeleton regulatory protein 1

associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas

NCBI chr15:2,886,661...2,913,975

G

caspase 3

associated with Breast Neoplasms

NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505

G

catalase

CTD Direct Evidence: therapeutic

PMID:12538496 PMID:22580338 PMID:23518002

NCBI chr18:33,383,005...33,422,447
Ensembl chr18:33,383,005...33,422,447

G

caveolin 1

treatment

associated with Mammary Neoplasms, Experimental
CTD Direct Evidence: marker/mechanism

PMID:15334058 PMID:15355971 PMID:20562527

RGD:2289106 RGD:8661780

NCBI chr14:55,458,934...55,494,563
Ensembl chr14:55,461,048...55,492,935

G

chromobox 4

associated with Carcinoma, Hepatocellular;

NCBI chr 9:1,799,847...1,807,500
Ensembl chr 9:1,802,047...1,807,690

G

chromobox 5

associated with Lung Neoplasms;

NCBI chr27:1,020,500...1,058,027
Ensembl chr27:1,039,594...1,049,788

G

C-C motif chemokine ligand 2

associated with Mammary Neoplasms, Experimental

NCBI chr 9:39,008,187...39,009,932

G

C-C motif chemokine ligand 20

CTD Direct Evidence: marker/mechanism

NCBI chr25:40,506,385...40,509,903
Ensembl chr25:40,506,753...40,509,709

G

C-C motif chemokine ligand 5

treatment

associated with Animal Mammary Neoplasms;

NCBI chr 9:37,817,409...37,823,852
Ensembl chr 9:37,817,305...37,823,852

G

cellular communication network factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr13:29,648,720...29,683,822
Ensembl chr13:29,648,639...29,679,732

G

cyclin A2

associated with Seminoma;protein:increased expression:testis

NCBI chr19:18,317,866...18,324,592
Ensembl chr19:18,318,004...18,323,691

G

cyclin D1

treatment

associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant
associated with stomach cancer; human cells in mouse model

PMID:18715616 PMID:27431311

RGD:13434926 RGD:152995400

NCBI chr18:48,501,905...48,509,684
Ensembl chr18:48,501,899...48,516,005

G

cyclin D2

associated with Breast Neoplasms;DNA:hypermethylated:brain

NCBI chr27:40,563,306...40,593,362
Ensembl chr27:40,564,921...40,594,255

G

cyclin E1

disease_progression

associated with non-small cell lung carcinoma
protein:altered processing

PMID:11212263 PMID:17671189

RGD:13673913 RGD:2289229

NCBI chr 1:121,688,622...121,697,533
Ensembl chr 1:121,688,796...121,697,649

G

C-C motif chemokine receptor 5

CTD Direct Evidence: marker/mechanism

NCBI chr20:42,293,288...42,297,952
Ensembl chr20:42,294,996...42,297,952

G

CD274 molecule

disease_progression

associated with ovarian cancer

NCBI chr 1:93,461,735...93,605,772
Ensembl chr 1:93,585,518...93,603,522

G

CD44 molecule

CTD Direct Evidence: marker/mechanism
associated with Carcinoma, Renal Cell;protein:increased expression:kidney

PMID:18026989 PMID:23098472

NCBI chr18:32,735,493...32,826,483
Ensembl chr18:32,737,907...32,827,107

G

CD82 molecule

associated with Prostatic Neoplasms;mRNA:decreased expression
associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain
associated with Prostatic Neoplasms;DNA:loss of heterozygosity
CTD Direct Evidence: therapeutic
associated with Carcinoma, Hepatocellular;mRNA:decreased expression
associated with Prostatic Neoplasms;mRNA:decreased expression:bone

PMID:9254900 PMID:9831222 PMID:11275982 PMID:12806379 PMID:15592684 More...

RGD:2289400 RGD:2289402 RGD:2289407 RGD:2289425 RGD:68869

NCBI chr18:44,658,414...44,707,897
Ensembl chr18:44,659,180...44,706,768

G

CD86 molecule

mRNA:decreased expression:mediastinal lymph node (rat)

NCBI chr33:25,256,267...25,318,855
Ensembl chr33:25,256,267...25,318,087

G

cadherin 1

treatment

associated with Prostatic Neoplasms
associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:17520682 PMID:18008331 PMID:22580338 PMID:27431311

RGD:152995400 RGD:2289488

NCBI chr 5:80,757,508...80,834,878
Ensembl chr 5:80,757,508...80,834,878

G

cadherin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:60,736,760...60,950,477
Ensembl chr 7:60,736,760...60,951,034

G

cyclin dependent kinase like 2

CTD Direct Evidence: marker/mechanism

NCBI chr32:158,140...206,860
Ensembl chr32:159,332...202,617

G

cyclin dependent kinase inhibitor 1A

associated with Melanoma;

NCBI chr12:5,746,898...5,755,103
Ensembl chr12:5,745,852...5,892,281

G

cyclin dependent kinase inhibitor 2A

associated with Paraganglioma, Extra-Adrenal;DNA:hypermethylation

NCBI chr11:41,223,316...41,226,056
Ensembl chr11:41,223,315...41,264,379

G

cofilin 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:51,404,649...51,408,240
Ensembl chr18:51,401,659...51,408,212

G

glycoprotein hormones, alpha polypeptide

associated with Breast Neoplasms;protein:increased expression:serum

NCBI chr12:46,610,801...46,629,322
Ensembl chr12:46,610,973...46,636,640

G

checkpoint kinase 1

associated with Pancreatic Neoplasms

NCBI chr 5:8,878,511...8,910,626
Ensembl chr 5:8,879,147...8,907,669

G

component of inhibitor of nuclear factor kappa B kinase complex

associated with prostate adenocarcinoma

NCBI chr28:12,964,670...13,001,557
Ensembl chr28:12,965,479...13,001,512

G

capicua transcriptional repressor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:112,081,775...112,105,093
Ensembl chr 1:112,082,265...112,105,082

G

claudin 7

NCBI chr 5:32,223,985...32,225,795
Ensembl chr 5:32,224,040...32,226,168

G

chloride intracellular channel 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:1,209,777...1,215,229
Ensembl chr12:1,209,780...1,215,229

G

clusterin

associated with Breast Neoplasms

NCBI chr25:29,982,811...29,999,565
Ensembl chr25:29,982,811...29,999,563

G

cAMP responsive element binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr37:15,921,214...15,978,492
Ensembl chr37:15,939,138...15,977,556

G

colony stimulating factor 1

associated with Prostatic Neoplasms

NCBI chr 6:42,028,454...42,047,028
Ensembl chr 6:42,034,149...42,049,371

G

colony stimulating factor 1 receptor

exacerbates

associated with Prostatic Neoplasms
associated with breast cancer
CTD Direct Evidence: marker/mechanism

PMID:1390197 PMID:18510570 PMID:25005824

RGD:150524287 RGD:2293638

NCBI chr 4:58,980,699...59,010,683
Ensembl chr 4:58,980,788...59,010,510

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

PMID:7543699 PMID:9018096

NCBI chr 9:22,529,643...22,532,326
Ensembl chr 9:22,530,698...22,533,108

G

cystatin A

CTD Direct Evidence: marker/mechanism

NCBI chr33:25,477,789...25,489,123
Ensembl chr33:25,478,055...25,489,121

G

cytotoxic T-lymphocyte associated protein 4

disease_progression

associated with Mammary Neoplasms, Experimental

PMID:15701862 PMID:18049334

RGD:4891518 RGD:7204722

NCBI chr37:12,647,712...12,653,874
Ensembl chr37:12,634,563...12,653,874

G

catenin beta 1

associated with Prostatic Neoplasms
CTD Direct Evidence: marker/mechanism

PMID:18008331 PMID:29106415

NCBI chr23:10,559,722...10,572,933
Ensembl chr23:10,559,718...10,572,927

G

cathepsin B

protein:increased expression:cerebrospinal fluid

NCBI chr25:26,048,237...26,056,570
Ensembl chr25:26,048,253...26,055,801

G

cathepsin D

protein:increased expression:oral cavity, oropharynx, hypopharynx (human)

NCBI chr18:46,010,440...46,019,457
Ensembl chr18:46,010,440...46,019,457

G

cathepsin H

protein:increased expression:cerebrospinal fluid

NCBI chr 3:58,103,284...58,113,958
Ensembl chr 3:58,103,291...58,113,718

G

cytosolic thiouridylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:105,795,273...105,800,722

G

cytosolic thiouridylase subunit 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:64,640,389...64,647,298
Ensembl chr 5:64,640,389...64,647,215

G

C-X3-C motif chemokine receptor 1

susceptibility

associated with Breast Neoplasms

NCBI chr23:8,937,069...8,954,738
Ensembl chr23:8,938,906...8,952,808

G

C-X-C motif chemokine ligand 12

treatment

associated with Pancreatic Carcinoma
CTD Direct Evidence: marker/mechanism
associated with Pancreatic Neoplasms

PMID:12761880 PMID:21312072 PMID:23743303 PMID:26330165

RGD:10398726 RGD:2317610

NCBI chr28:2,895,916...2,903,543

G

C-X-C motif chemokine receptor 3

associated with Mammary Neoplasms, Experimental

NCBI chr X:55,882,433...55,884,582
Ensembl chr X:55,882,433...55,884,582

G

C-X-C motif chemokine receptor 4

ameliorates
disease_progression
severity

associated with lung cancer; human cells in mouse model
associated with lung non-small cell carcinoma; protein:increased expression:lung (human)
associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human)
associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human)
associated with oral squamous cell carcinoma
human cells in mouse model;associated with lung cancer
CTD Direct Evidence: marker/mechanism
associated with osteosarcoma;protein:increased expression:bone (human)
associated with pancreatic cancer

PMID:16230077 PMID:16322285 PMID:17634424 PMID:18487224 PMID:21312072 More...

RGD:151708730 RGD:152023741 RGD:152023745 RGD:152023746 RGD:152025556 RGD:152177475 RGD:152177476 RGD:152177478 RGD:152177479

NCBI chr19:38,874,650...38,877,740
Ensembl chr19:38,874,145...38,877,740

G

cytochrome P450 family 19 subfamily A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr30:16,954,020...17,056,728
Ensembl chr30:16,957,215...16,988,353

G

DAB2 interacting protein

severity

associated with colorectal cancer;protein:decreased expression:colorectum (human)

NCBI chr 9:60,725,887...60,918,242
Ensembl chr 9:60,726,809...60,918,139

G

death associated protein kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:72,278,939...72,448,907
Ensembl chr 1:72,280,103...72,447,822

G

death domain associated protein

NCBI chr12:2,755,960...2,760,687
Ensembl chr12:2,755,960...2,761,340

G

decorin

associated with Breast Neoplasms

NCBI chr15:31,833,492...31,887,699
Ensembl chr15:31,833,746...31,877,417

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA:increased expression:ovary (human)
protein:increased expression:bone (human)

PMID:28743276 PMID:29039472

RGD:151347541 RGD:151347601

NCBI chr12:653,800...671,190
Ensembl chr12:653,807...670,543

G

discoidin domain receptor tyrosine kinase 2

ameliorates

associated with melanoma;

NCBI chr38:20,002,984...20,152,930
Ensembl chr38:20,008,057...20,152,275

G

DEAD-box helicase 3 X-linked

human cells in mouse model

NCBI chr X:35,759,367...35,789,759
Ensembl chr X:35,759,416...35,789,774

G

DEK proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr35:17,014,802...17,045,308
Ensembl chr35:17,016,231...17,044,749

G

dihydrofolate reductase

disease_progression

CTD Direct Evidence: marker/mechanism

PMID:8149482 PMID:19159907

NCBI chr 3:26,521,214...26,556,065

G

iodothyronine deiodinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:69,696,779...69,698,880

G

dystrophin

CTD Direct Evidence: marker/mechanism

NCBI chr X:26,290,903...28,444,635
Ensembl chr X:26,290,910...28,333,576

G

DNA methyltransferase 3 beta

associated with Uterine Cervical Neoplasms;

NCBI chr24:22,096,386...22,123,378
Ensembl chr24:22,096,349...22,122,900

G

dihydropyrimidine dehydrogenase

treatment

CTD Direct Evidence: marker/mechanism
associated with Colonic Neoplasms

PMID:11383214 PMID:17611699

NCBI chr 6:51,789,786...52,564,802
Ensembl chr 6:51,814,573...52,580,923

G

E2F transcription factor 8

CTD Direct Evidence: marker/mechanism

NCBI chr21:41,340,410...41,358,261
Ensembl chr21:41,340,969...41,357,206

G

endothelin 1

NCBI chr35:11,808,892...11,815,383
Ensembl chr35:11,808,892...11,815,383

G

endothelin receptor type A

associated with Bladder Neoplasms

NCBI chr15:45,823,472...45,878,527
Ensembl chr15:45,823,560...45,876,463

G

eukaryotic translation elongation factor 1 beta 2

CTD Direct Evidence: marker/mechanism

PMID:17085005 PMID:20562527

NCBI chr37:14,713,927...14,716,894
Ensembl chr37:14,714,017...14,716,850

G

eukaryotic translation elongation factor 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:55,577,413...55,586,422
Ensembl chr20:55,522,213...55,586,126

G

ephrin B2

associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human)

NCBI chr22:55,567,992...55,609,210
Ensembl chr22:55,566,039...55,609,443

G

epidermal growth factor

CTD Direct Evidence: marker/mechanism

PMID:21942447 PMID:23064031

NCBI chr32:30,073,541...30,166,904
Ensembl chr32:30,073,950...30,166,295

G

epidermal growth factor receptor

CTD Direct Evidence: marker/mechanism

PMID:17369752 PMID:17575224 PMID:23867902

NCBI chr18:5,983,669...6,044,092
Ensembl chr18:5,982,770...6,042,631

G

euchromatic histone lysine methyltransferase 2

associated with lung neoplasms;
CTD Direct Evidence: marker/mechanism

PMID:20940408 PMID:25115793

NCBI chr12:1,341,202...1,354,602
Ensembl chr12:1,341,191...1,354,584

G

eukaryotic translation initiation factor 1A X-linked

CTD Direct Evidence: marker/mechanism

NCBI chr X:16,081,335...16,102,627
Ensembl chr X:16,081,392...16,099,142

G

eukaryotic translation initiation factor 4A2

CTD Direct Evidence: marker/mechanism

NCBI chr34:19,354,739...19,361,021
Ensembl chr34:19,354,825...19,409,844

G

elongator acetyltransferase complex subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr25:29,415,229...29,507,159
Ensembl chr25:29,415,924...29,507,098

G

EMAP like 4

CTD Direct Evidence: marker/mechanism

PMID:22986231 PMID:22999080

NCBI chr17:33,774,478...33,935,478
Ensembl chr17:33,774,140...33,934,147

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:18,586,886...18,697,339
Ensembl chr13:18,587,129...18,697,324

G

epithelial cell adhesion molecule

NCBI chr10:49,446,165...49,498,690
Ensembl chr10:49,485,746...49,498,475

G

erythropoietin

CTD Direct Evidence: marker/mechanism

NCBI chr 6:8,994,211...8,995,954
Ensembl chr 6:8,994,211...8,996,144

G

erythropoietin receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:49,945,777...49,950,856
Ensembl chr20:49,945,777...49,950,856

G

erb-b2 receptor tyrosine kinase 2

CTD Direct Evidence: marker/mechanism
rat gene in a mouse model

PMID:11238891 PMID:16984552

NCBI chr 9:22,760,373...22,785,367
Ensembl chr 9:22,759,256...22,785,294

G

erb-b2 receptor tyrosine kinase 3

disease_progression

CTD Direct Evidence: marker/mechanism
associated with lung adenocarcinoma
associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus
associated with Prostatic Neoplasms;protein:alternative form

PMID:17634423 PMID:18559590 PMID:26254096 PMID:28114269

RGD:126790470 RGD:2289944 RGD:2298500

NCBI chr10:406,856...424,746
Ensembl chr10:406,633...424,264

G

erb-b2 receptor tyrosine kinase 4

disease_progression

associated with lung adenocarcinoma

NCBI chr37:19,029,647...20,134,576
Ensembl chr37:19,037,217...20,134,426

G

ERCC excision repair 1, endonuclease non-catalytic subunit

disease_progression

CTD Direct Evidence: marker/mechanism
associated with Melanoma

PMID:20801905 PMID:26202595

NCBI chr 1:110,130,353...110,146,660
Ensembl chr 1:110,130,481...110,146,602

G

ERCC excision repair 4, endonuclease catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 6:29,193,192...29,226,935
Ensembl chr 6:29,196,421...29,226,887

G

endoplasmic reticulum protein 29

CTD Direct Evidence: marker/mechanism

NCBI chr26:9,608,352...9,616,711
Ensembl chr26:9,608,399...9,616,338

G

estrogen receptor 1

CTD Direct Evidence: marker/mechanism

PMID:20104649 PMID:35044086

NCBI chr 1:42,081,952...42,368,544
Ensembl chr 1:42,081,969...42,368,544

G

ETS variant transcription factor 4

CTD Direct Evidence: marker/mechanism

NCBI chr 9:19,715,259...19,731,085
Ensembl chr 9:19,715,535...19,730,456

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

associated with osteosarcoma
associated with lung non-small cell carcinoma
associated with stomach cancer;protein:increased expression:stomach

PMID:20132185 PMID:24097870 PMID:26265454

RGD:11532507 RGD:126779607 RGD:126781716

NCBI chr16:1,926,443...1,991,995
Ensembl chr16:1,925,956...1,991,838

G

ezrin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:48,160,206...48,210,036
Ensembl chr 1:48,160,206...48,210,036

G

coagulation factor II, thrombin

associated with Carcinoma, Small cell;protein:increased expression:brain

NCBI chr18:42,782,744...42,799,531
Ensembl chr18:42,782,751...42,799,459

G

Fas associated via death domain

CTD Direct Evidence: marker/mechanism

NCBI chr18:48,087,447...48,094,497

G

Fas cell surface death receptor

associated with Breast Neoplasms;protein:decreased expression:breast
associated with Mammary Neoplasms;protein:decreased expression:lung

PMID:17352235 PMID:17918178

RGD:2290048 RGD:2290053

NCBI chr26:38,738,811...38,763,298
Ensembl chr26:38,737,611...38,763,321

G

Fas ligand

associated with Breast Neoplasms;protein:decreased expression:breast

NCBI chr 7:26,335,837...26,344,224
Ensembl chr 7:26,335,846...26,344,224

G

fibroblast growth factor 13

CTD Direct Evidence: marker/mechanism

NCBI chr X:108,658,113...109,156,096
Ensembl chr X:108,658,941...109,156,594

G

fibroblast growth factor receptor 1

associated with prostate adenocarcinoma

NCBI chr16:27,029,902...27,080,514
Ensembl chr16:27,031,588...27,078,261

G

fms related receptor tyrosine kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr25:11,231,958...11,410,379
Ensembl chr25:11,231,737...11,407,621

G

fibronectin 1

treatment

associated with stomach cancer; human cells in mouse model

NCBI chr37:22,456,854...22,522,410
Ensembl chr37:22,420,428...22,523,123

G

fascin actin-bundling protein 1

associated with Pancreatic Neoplasms

NCBI chr 6:12,360,849...12,370,906
Ensembl chr 6:12,354,599...12,370,808

G

ferritin light chain

CTD Direct Evidence: marker/mechanism

NCBI chr 1:107,418,457...107,419,923
Ensembl chr 1:107,418,458...107,419,923

G

GRB2 associated binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr21:20,414,903...20,605,807
Ensembl chr21:20,277,507...20,606,736

G

growth differentiation factor 15

CTD Direct Evidence: marker/mechanism

NCBI chr20:44,633,131...44,636,842
Ensembl chr20:44,634,588...44,636,821

G

gap junction protein beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:55,565,995...55,575,332
Ensembl chr X:55,573,808...55,574,659

G

glycoprotein Ib platelet subunit alpha

associated with Melanoma, Experimental

NCBI chr 5:31,681,605...31,683,261

G

glycerophosphocholine phosphodiesterase 1

CTD Direct Evidence: marker/mechanism

NCBI chr24:16,153,622...16,203,155
Ensembl chr24:16,148,035...16,220,757

G

glucose-6-phosphate isomerase

NCBI chr 1:117,922,380...117,948,325
Ensembl chr 1:117,922,635...117,948,316

G

glutathione peroxidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:39,322,040...39,325,833
Ensembl chr 8:39,322,034...39,325,817

G

hyaluronan binding protein 2

treatment

associated with Thyroid Neoplasms

NCBI chr28:24,489,665...24,522,336
Ensembl chr28:24,489,773...24,522,263

G

hepatitis A virus cellular receptor 2

disease_progression

DNA:polymorphisms: : +4259T>G (human)

NCBI chr 4:53,018,990...53,032,035
Ensembl chr 4:53,012,234...53,033,393

G

histone deacetylase 3

associated with Anaphylaxis;
CTD Direct Evidence: marker/mechanism

PMID:24619412 PMID:34973135

NCBI chr 2:36,583,283...36,598,121
Ensembl chr 2:36,583,283...36,597,682

G

hepatocyte growth factor

CTD Direct Evidence: marker/mechanism
associated with Melanoma;
associated with Mammary Neoplasms, Experimental;
associated with Pancreatic Neoplasms

PMID:10688652 PMID:11893931 PMID:16459153 PMID:25971889

RGD:2317904 RGD:8548538 RGD:8548625

NCBI chr18:21,329,688...21,410,257
Ensembl chr18:21,332,817...21,410,263

G

heparanase

CTD Direct Evidence: marker/mechanism

NCBI chr32:7,166,437...7,199,659
Ensembl chr32:7,167,856...7,199,665

G

histamine receptor H2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:37,333,843...37,407,146
Ensembl chr 4:37,275,852...37,386,072

G

heat shock protein 90 alpha family class A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:70,091,203...70,096,107
Ensembl chr 8:70,092,217...70,095,243

G

integrin binding sialoprotein

CTD Direct Evidence: marker/mechanism

PMID:22407340 PMID:24980816

NCBI chr32:11,187,188...11,200,860
Ensembl chr32:11,187,160...11,200,846

G

intercellular adhesion molecule 1

associated with Pancreatic Neoplasms;protein:increased expression:serum
associated with Melanoma, Cutaneous Malignant

PMID:10465581 PMID:12923961

RGD:2325163 RGD:8547593

NCBI chr20:50,818,715...50,827,914
Ensembl chr20:50,818,715...50,827,914

G

inhibitor of DNA binding 1

CTD Direct Evidence: therapeutic

NCBI chr24:21,094,339...21,096,276
Ensembl chr24:21,094,755...21,096,276

G

insulin like growth factor 1

CTD Direct Evidence: marker/mechanism
associated with Uveal Melanoma;protein:increased expression:serum:
associated with Pancreatic Neoplasms

PMID:18398872 PMID:19375852 PMID:23197685

RGD:2317643 RGD:8548834

NCBI chr15:41,203,320...41,275,964
Ensembl chr15:41,202,518...41,275,794

G

insulin like growth factor 1 receptor

associated with Pancreatic Neoplasms

NCBI chr 3:41,795,337...42,096,255
Ensembl chr 3:41,794,623...42,090,387

G

insulin like growth factor 2

associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum:

NCBI chr18:46,294,036...46,311,982
Ensembl chr18:46,294,019...46,311,982

G

IKAROS family zinc finger 1

associated with colorectal cancer;DNA:polymorphisms:

NCBI chr18:1,661,851...1,750,987
Ensembl chr18:1,661,690...1,770,768

G

interleukin 10

NCBI chr 7:5,933,285...5,937,057
Ensembl chr 7:5,933,285...5,937,057

G

interleukin 18

CTD Direct Evidence: marker/mechanism
protein:increased expression:serum
associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human)
associated with breast cancer;protein:increased expression:serum

PMID:11215816 PMID:12209760 PMID:12748951 PMID:19152241

RGD:4889862 RGD:8655866 RGD:8655899

NCBI chr 5:20,972,742...20,995,327
Ensembl chr 5:20,972,871...20,995,348

G

interleukin 2

treatment

associated with neuroblastoma.
CTD Direct Evidence: therapeutic
associated with melanoma
associated with melanoma;

PMID:8610104 PMID:8642346 PMID:9362156 PMID:17105418

RGD:14747043 RGD:14865005 RGD:8663438

NCBI chr19:17,750,780...17,756,394
Ensembl chr19:17,750,780...17,756,394

G

interleukin 6

treatment

associated with stomach cancer, human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:21937440 PMID:26101800 PMID:28186964

NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519

G

integrin subunit alpha 6

NCBI chr36:16,777,363...16,858,725
Ensembl chr36:16,776,863...16,855,449

G

integrin subunit beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:3,728,472...3,757,696
Ensembl chr 2:3,670,596...3,756,961

G

integrin subunit beta 3

mRNA, protein:increased expression:lung
associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human)

PMID:16831169 PMID:21107114

RGD:5037225 RGD:6907406

NCBI chr 9:9,179,667...9,231,061
Ensembl chr 9:9,182,562...9,231,451

G

Janus kinase 2

treatment

associated with stomach cancer, human cells in mouse model

NCBI chr 1:93,321,055...93,438,898
Ensembl chr 1:93,142,635...93,435,997

G

junction plakoglobin

associated with Ovarian Neoplasms

NCBI chr 9:21,028,773...21,053,071
Ensembl chr 9:21,028,828...21,053,071

G

lysine demethylase 6A

disease_progression

associated with lung adenocarcinoma;protein:increased expression:brain (human)

NCBI chr X:38,745,854...38,964,029
Ensembl chr X:38,745,854...38,959,842

G

kinase insert domain receptor

associated with Carcinoma, Renal Cell

NCBI chr13:47,442,861...47,484,574
Ensembl chr13:47,442,764...47,485,042

G

kinesin family member 2C

disease_progression

associated with colorectal cancer

NCBI chr15:15,558,024...15,579,371
Ensembl chr15:15,558,021...15,579,217

G

KiSS-1 metastasis suppressor

associated with Ovarian Neoplasms

NCBI chr38:768,333...774,328
Ensembl chr38:768,585...773,382

G

lysine methyltransferase 2B

associated with lung adenocarcinoma

NCBI chr 1:116,894,024...116,913,464
Ensembl chr 1:116,893,074...116,913,472

G

lysine methyltransferase 2D

disease_progression

associated with colorectal cancer;DNA:mutations::

NCBI chr27:5,516,866...5,556,303
Ensembl chr27:5,521,804...5,553,490

G

KRAS proto-oncogene, GTPase

treatment
disease_progression

associated with colorectal cancer; DNA:mutation:cds:
associated with stomach cancer; human cells in mouse model
associated with colorectal cancer;DNA:mutation: :
associated with Fibrosarcoma;mRNA,protein:decreased expression::
CTD Direct Evidence: marker/mechanism
associated with colorectal cancer;DNA:mutations: :

PMID:3552201 PMID:8635384 PMID:26210240 PMID:27264476 PMID:27431311 More...

RGD:11086960 RGD:11570402 RGD:14398745 RGD:14398751 RGD:152995400

NCBI chr27:22,261,753...22,296,704
Ensembl chr27:22,257,941...22,293,369

G

keratin 14

mRNA:decreased expression:epithelial cell

NCBI chr 9:21,190,672...21,195,060
Ensembl chr 9:21,156,045...21,265,564

G

keratin 20

associated with Colorectal Neoplasms

NCBI chr 9:21,808,171...21,818,301
Ensembl chr 9:21,808,548...21,817,387

G

L1 cell adhesion molecule

treatment

associated with Lung Neoplasms;
associated with Pancreatic Neoplasms;

PMID:22095073 PMID:22307136

RGD:11570404 RGD:11570503

NCBI chr X:121,708,695...121,722,819
Ensembl chr X:121,708,894...121,733,365

G

laminin subunit gamma 2

associated with lung adenocarcinoma;

NCBI chr 7:16,543,541...16,625,304
Ensembl chr 7:16,569,086...16,624,085

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:55,328,118...55,342,535
Ensembl chr 9:55,328,133...55,332,038

G

leukocyte cell derived chemotaxin 2

CTD Direct Evidence: therapeutic

NCBI chr11:23,864,062...23,873,720
Ensembl chr11:23,864,064...23,886,226

G

lymphoid enhancer binding factor 1

CTD Direct Evidence: marker/mechanism
associated with prostate cancer

PMID:27067790 PMID:27811057

NCBI chr32:28,516,002...28,633,759
Ensembl chr32:28,517,108...28,634,019

G

galectin 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:30,977,438...30,994,711
Ensembl chr 8:30,983,633...30,994,705

G

LLGL scribble cell polarity complex component 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:4,975,309...5,008,383
Ensembl chr 9:4,975,660...4,996,775

G

thioredoxin-like

CTD Direct Evidence: marker/mechanism

NCBI chr X:82,986,288...82,986,753

G

mucin-6

disease_progression

associated with cholangiocarcinoma

NCBI chr18:45,359,412...45,376,678

G

phosphatidylinositol 3-kinase regulatory subunit gamma

associated with Adenocarcinoma, Colon

NCBI chr15:14,222,059...14,357,200
Ensembl chr15:14,235,824...14,353,832

G

calmodulin-like protein 3

ameliorates

associated with hepatocellular carcinoma; protein:decreased expression:liver (human)
associated with hepatocellular carcinoma; human cells in mouse model

NCBI chr 2:30,410,830...30,411,981

G

peptidylprolyl isomerase A (cyclophilin A) pseudogene

CTD Direct Evidence: marker/mechanism

NCBI chr 7:80,937,433...80,938,175

G

chemokine (C-C motif) ligand 3

NCBI chr 9:37,708,561...37,710,209
Ensembl chr 9:37,676,966...37,710,209

G

sulfotransferase 1E1

associated with Colonic Neoplasms;protein:increased expression:liver

NCBI chr13:59,323,430...59,343,745

G

cystatin-C-like

protein:decreased expression:cerebrospinal fluid

NCBI chr23:49,562...53,618

G

lymphocyte antigen 96

CTD Direct Evidence: marker/mechanism

NCBI chr29:22,493,757...22,515,147
Ensembl chr29:22,493,896...22,515,117

G

MET transcriptional regulator MACC1

treatment

associated with stomach cancer; human cells in mouse model
CTD Direct Evidence: marker/mechanism

PMID:27431311 PMID:36008464

NCBI chr14:34,189,983...34,271,998
Ensembl chr14:34,075,463...34,251,330

G

mitogen-activated protein kinase kinase 4

disease_progression

associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human)

NCBI chr 5:36,142,610...36,243,673
Ensembl chr 5:36,118,388...36,241,296

G

mitogen-activated protein kinase 1

treatment

CTD Direct Evidence: marker/mechanism
associated with prostate adenocarcinoma

PMID:22139534 PMID:22580338

NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998

G

mitogen-activated protein kinase 3

CTD Direct Evidence: marker/mechanism

NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425

G

mitogen-activated protein kinase 9

CTD Direct Evidence: therapeutic
associated with Colorectal Neoplasms

PMID:21779479 PMID:25205654

NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119

G

mediator complex subunit 28

CTD Direct Evidence: marker/mechanism

NCBI chr 3:62,887,095...62,895,588
Ensembl chr 3:62,890,515...62,895,562

G

MET proto-oncogene, receptor tyrosine kinase

disease_progression

associated with Squamous Cell Carcinoma of the Tongue;
CTD Direct Evidence: marker/mechanism

PMID:20080979 PMID:21225626 PMID:22704061

NCBI chr14:55,599,047...55,711,626
Ensembl chr14:55,598,337...55,724,027

G

microRNA mir-125a

CTD Direct Evidence: marker/mechanism
associated with stomach cancer;

PMID:19487542 PMID:30117667

NCBI chr 1:105,400,273...105,400,332
Ensembl chr 1:105,400,270...105,400,337

G

microRNA mir-130a

CTD Direct Evidence: marker/mechanism

NCBI chr18:38,543,618...38,543,679
Ensembl chr18:38,543,618...38,543,681

G

microRNA mir-136

ameliorates

associated with stomach cancer;human cells in mouse model

NCBI chr 8:69,106,615...69,106,670
Ensembl chr 8:69,106,598...69,106,687

G

microRNA mir-148b

CTD Direct Evidence: marker/mechanism

NCBI chr27:975,146...975,206
Ensembl chr27:975,131...975,220

G

microRNA mir-152

associated with Castration-Resistant Prostatic Neoplasms

NCBI chr 9:24,335,161...24,335,219
Ensembl chr 9:24,335,146...24,335,225

G

microRNA mir-155

CTD Direct Evidence: marker/mechanism

PMID:19487542 PMID:27692344 PMID:27856635

NCBI chr31:21,078,768...21,078,828
Ensembl chr31:21,078,758...21,078,833

G

microRNA mir-181c

CTD Direct Evidence: marker/mechanism

NCBI chr20:48,593,343...48,593,403
Ensembl chr20:48,593,325...48,593,421

G

microRNA mir-193a

exacerbates

associated with colorectal cancer; miRNA:decreased expression:colorectum (human)
associated with lung non-small cell carcinoma; human cells in mouse model

PMID:24469061 PMID:25232258 PMID:30685413

RGD:153344566 RGD:153344592 RGD:153344599

NCBI chr 9:41,316,481...41,316,536
Ensembl chr 9:41,316,474...41,316,542

G

microRNA mir-197

CTD Direct Evidence: marker/mechanism

NCBI chr 6:42,271,719...42,271,779
Ensembl chr 6:42,271,708...42,271,797

G

microRNA mir-19a

CTD Direct Evidence: marker/mechanism

NCBI chr22:42,478,298...42,478,355
Ensembl chr22:42,478,285...42,478,366

G

microRNA mir-205

CTD Direct Evidence: marker/mechanism

NCBI chr 7:8,090,511...8,090,579
Ensembl chr 7:8,090,511...8,090,579

G

microRNA mir-20a

associated with colorectal cancer

NCBI chr22:42,478,462...42,478,520
Ensembl chr22:42,478,462...42,478,520

G

microRNA mir-20b

CTD Direct Evidence: marker/mechanism

NCBI chr X:104,896,091...104,896,158
Ensembl chr X:104,896,091...104,896,158

G

microRNA mir-21

treatment
ameliorates

associated with prostate carcinoma; human cells in mouse model
CTD Direct Evidence: marker/mechanism
human cells in mouse model;associated with breast cancer

PMID:18270520 PMID:26101800 PMID:32736696

RGD:152998873 RGD:152998897

NCBI chr 9:34,340,550...34,340,609
Ensembl chr 9:34,340,533...34,340,624

G

microRNA mir-221

CTD Direct Evidence: marker/mechanism

NCBI chr X:39,523,890...39,523,951
Ensembl chr X:39,523,885...39,523,954

G

microRNA mir-222

CTD Direct Evidence: marker/mechanism

NCBI chr X:39,524,519...39,524,608
Ensembl chr X:39,524,519...39,524,608

G

microRNA mir-224

CTD Direct Evidence: marker/mechanism
associated with colorectal cancer; mRNA:increased expression:colorectal mucosa:

PMID:19487542 PMID:25919696

NCBI chr X:119,925,345...119,925,413
Ensembl chr X:119,925,345...119,925,413

G

microRNA mir-30a

CTD Direct Evidence: marker/mechanism

NCBI chr12:33,783,894...33,783,956
Ensembl chr12:33,783,891...33,783,961

G

microRNA mir-30e

CTD Direct Evidence: marker/mechanism

NCBI chr15:2,283,306...2,283,369
Ensembl chr15:2,283,306...2,283,369

G

microRNA mir-31

disease_progression
treatment

CTD Direct Evidence: marker/mechanism
associated with colorectal cancer;RNA:increased expression:colorectum (human)
associated with stomach cancer;human cells in mouse model

PMID:19487542 PMID:26497852 PMID:27174918 PMID:30108104

RGD:153297776 RGD:153297806 RGD:153297811

NCBI chr11:40,904,438...40,904,496
Ensembl chr11:40,904,437...40,904,503

G

microRNA mir-335

lung metastasis

NCBI chr14:6,444,861...6,444,918
Ensembl chr14:6,444,847...6,444,932

G

microRNA mir-342

CTD Direct Evidence: marker/mechanism

NCBI chr 8:68,424,656...68,424,718

G

microRNA mir-346

CTD Direct Evidence: marker/mechanism

PMID:27501413 PMID:27777383

NCBI chr 4:34,073,335...34,073,429
Ensembl chr 4:34,073,335...34,073,429

G

microRNA mir-34b

CTD Direct Evidence: marker/mechanism

NCBI chr 5:21,558,685...21,558,768
Ensembl chr 5:21,558,685...21,558,768